



Endoscopic Retrograde Cholangiopancreatography – Utilization and outcomes in a 10-year population based cohort

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002689
Article Type:	Research
Date Submitted by the Author:	05-Feb-2013
Complete List of Authors:	Coelho-Prabhu, Nayantara; Mayo Clinic, Gastroenterology and Hepatology Shah, Nilay; Mayo Clinic, Health Care Policy and Research Van Houten, Holly; Mayo Clinic, Health Care Policy and Research Kamath, Patrick; Mayo Clinic, Gastroenterology and Hepatology Baron, Todd; Mayo Clinic, Gastroenterology and Hepatology
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Evidence based practice, Gastroenterology and hepatology
Keywords:	Adult gastroenterology < GASTROENTEROLOGY, Endoscopy < GASTROENTEROLOGY, Hepatobiliary disease < GASTROENTEROLOGY, Pancreatic disease < GASTROENTEROLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Endoscopic Retrograde Cholangiopancreatography – Utilization and outcomes in a 10-year**
4 **population based cohort**
5
6

7
8 Nayantara Coelho-Prabhu, MD¹; Nilay D. Shah, PhD²; Holly Van Houten²;
9

10 Patrick S Kamath, MD¹; Todd H Baron, MD, FASGE¹
11
12

13
14
15 ¹ Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
16

17 ² Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN, USA
18
19

20
21
22 **Financial support and disclosure** – none.
23

24 **Corresponding author** – Nayantara Coelho-Prabhu, MD
25

26 200 First Street SW

27 Rochester, MN 55905, USA

28 Coelhoprabhu.nayantara@mayo.edu

29 Tel – 001-507-284-2407

30 Fax – 001-507-284-0538
31

32 Extra data is available by contacting the corresponding author.
33
34

35 **Word count** – Text – 3154
36

37 Tables – 5
38

39 Figures – 1
40
41
42
43
44

45 **Keywords:** ERCP, utilization, complications, hospitalization
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SUMMARY

Article Focus:

- Due to increasing use of quality metrics, accurate measures of utilization and procedural adverse event risks are necessary to establish benchmarks for quality, and are best determined from community-based studies.
- There are no reports of community-based utilization of ERCP in the US.
- The aims of this population-based study were to determine the utilization of ERCP including changes over time, the incidence of inpatient admissions for adverse events within 30 days of ERCP, and risk factors for procedural related adverse events.

Key Messages:

- Population utilization of ERCP in Olmsted County MN rose over the ten year period from 1997 to 2006, driven specifically by increases in therapeutic procedures. The most common indications for ERCP were therapy of choledocholithiasis and to determine etiology of acute pancreatitis.
- Admissions within 30 days after ERCP are common, but are usually unrelated. Complications of ERCP remain rare at 5.3% and no deaths were directly related.
- Risk factors associated with adverse events from ERCP include younger age, BMI ≥ 35 , pancreatic duct cannulation, outpatient procedures, intraprocedure sphincterotomy bleeding, difficulty grade, and patient's first ERCP.

Strengths and Limitations:

Strengths:

- Population-based epidemiologic research can be conducted in Olmsted County because medical care is virtually self-contained within the community.
- The unique advantage of our data is that Mayo Clinic is the only center performing ERCP in the entire county and, therefore, population based utilization and adverse events of ERCP with full details of procedures and subsequent hospitalizations can be assessed.

Limitations:

- The study is a retrospective review with inherent potential biases.
- The skills of the endoscopists are likely at a higher level than endoscopists in smaller community hospitals. Therefore, the adverse event rate in this community setting could be lower than one would expect in other community settings.

ABSTRACT

Objective: To determine utilization of ERCP; incidence of inpatient admissions for complications occurring within 30 days of ERCP; and risk factors for procedural related complications, in a population based study.

Design: Retrospective cohort study

Setting: Olmsted County, MN

Participants: All adult residents of Olmsted County, MN, who underwent ERCP from 1997 to 2006.

Interventions: Diagnostic and therapeutic ERCPs were assessed.

Primary and Secondary outcome measures: Patient and procedural characteristics and complications within 30 days; and rates of ERCP utilization and unplanned admissions and risk factors for admissions.

Results: In ten years, 1072 ERCPs were performed on 827 individual patients. Average utilization of ERCP was 83.1 ERCPs/100,000 persons/year, with an increase from 58.0 to 104.8 ERCPs/100,000 persons/year over time, driven by increases in therapeutic procedures. Within 30 days after 236 procedures, 62 admissions were definitely related to the index ERCP. The complication rate was 5.3%, including pancreatitis(26, 2.4%), infection/cholangitis(16, 1.5%),

1
2
3 bleeding(15, 1.4%), and perforation(4, 0.37%). 30-day mortality was 2.4%; none of which were
4 directly related to the ERCP or complications thereof. Risk factors identified through
5
6 directly related to the ERCP or complications thereof. Risk factors identified through
7
8 multivariate analysis to be associated with adverse events included: age <45 years(p=0.0498);
9
10 BMI \geq 35(p=0.0024); pancreatic duct cannulation(p=0.0026); outpatient procedure(p<0.0001);
11
12 intraprocedure sphincterotomy bleeding(P <0.0001); difficulty grade(P =0.115); and patient's first
13
14 ERCP(P =0.0394).
15
16
17
18
19

20 **Limitations:** Retrospective study.
21
22
23

24 **Conclusions:** Population utilization of ERCP rose during the study period, specifically in
25
26 therapeutic procedures. Admissions within 30 days of ERCP are common, but often unrelated.
27
28 Complications of ERCP remain rare and deaths quite unusual.
29
30
31
32
33
34
35
36
37
38

39 **Abbreviations:**

40 AE – adverse event

41 EGD – esophagogastroduodenoscopy

42 ERCP - endoscopic retrograde cholangiopancreatography

43 EUS – endoscopic ultrasound

44 MRCP - magnetic resonance cholangiopancreatography
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BACKGROUND

Since its first description in 1968, endoscopic retrograde cholangiopancreatography (ERCP) has become an established modality for the diagnosis and treatment of pancreaticobiliary disorders[1, 2]. Over the years, ERCP has evolved from a purely diagnostic, to a mainly therapeutic procedure. Around 500,000 ERCPs are performed annually in the United States (US) with adverse event (AE) rates between 4% and 10%, [3] and mortality between 0.05% and 1% [4-7]. The most common AEs following ERCP include pancreatitis, hemorrhage, and infection, which occurred in 4% to 7% of procedures [3, 6, 8]. There is an increased risk of AEs after therapeutic procedures and in patients with suspected Sphincter of Oddi dysfunction [6]. Since ERCP is the endoscopic procedure with the highest cost and AE rates, diagnostic ERCP is now avoided in favor of other diagnostic modalities such as less-invasive endoscopic ultrasound (EUS) and non-invasive magnetic resonance cholangiopancreatography (MRCP) [2, 3, 9]. In an era of increasing utilization of quality metrics, accurate measures of utilization rates and procedural adverse event risks are necessary to establish meaningful benchmarks for quality, and are best determined from community-based studies.

There are no reports of community-based utilization of ERCP in the US, but there are several from Europe [8, 10]. Published reports of ERCP related AEs have all been single-centered or multi-centered studies from tertiary care centers and affected by referral bias, leading to high estimates of risk that may not apply to the general population. All adverse events of procedures done at tertiary care centers may not be captured since the patients may seek care for AEs closer to their homes and thus, lost to follow-up.

The aims of this population-based study were to determine (1) the utilization of ERCP, including changes over time; (2) the incidence of inpatient admissions for AEs within 30 days of

1
2
3 ERCP; and (3) risk factors for procedural related AEs among residents of Olmsted County, MN
4
5 over a ten-year period from 1997-2006. The findings of this study are unique, as they represent
6
7 population based estimates of utilization and risks associated with ERCP and may serve as more
8
9 accurate and clinically meaningful data for clinical decision making and development of quality
10
11 benchmarks.
12
13

14 15 16 17 18 **METHODS**

19
20 Study Design: A retrospective cohort study was conducted with approval of the Institutional
21
22 Review Board of Mayo Clinic in compliance with federal regulations of the U.S. Department of
23
24 Health and Human Services for protection of human subjects and the Health Information
25
26 Protection and Portability Act. Billing records from Mayo Clinic and associated hospitals were
27
28 queried for Olmsted County residents who had undergone an ERCP during a ten-year period
29
30 from January 1, 1997 to December 31, 2006. ERCPs were identified using CPT codes for ERCP,
31
32 including 43260, 43261, 43262, 43263, 43264, 43265, 43267, 43268, 43269, 43271, 43272, and
33
34 47999. Utilization characteristics for EUS were determined in the same population using codes
35
36 43232, 43238, and 43242 and for MRCP using codes 74181, 74182, and 74183. Subjects also
37
38 had to be age ≥ 18 years, live in Olmsted County, and have valid authorization to review medical
39
40 records for research purposes in accordance with Minnesota State statutes.
41
42
43
44

45
46 Population-based epidemiologic research can be conducted in Olmsted County because
47
48 medical care is virtually self-contained within the community. Olmsted County comprises over
49
50 100,000 persons, of whom 85% are Caucasian and 50% are women; socio-demographically, the
51
52 community is similar to the US population. Over half of the county's population is seen at one of
53
54 the Mayo Clinic facilities; 95% of local residents will have had at least one medical contact with
55
56
57
58
59
60

1
2
3 a local care provider (*e.g.*, for dental X-rays, sports physical examinations, pre-employment
4 examinations, minor illness, and routine medical care) during any 4-year period[11]. Mayo
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Clinic has a common medical record system with its two affiliated hospitals (Saint Mary's and Rochester Methodist) for 90 years. Mayo Clinic's single record system contains both inpatient and outpatient data. Diagnoses and surgical procedures recorded in these records are indexed. It includes diagnoses made for outpatients seen in office or clinic consultations, emergency room visits, and diagnoses recorded for hospital inpatients, autopsy examinations, or on death certificates. The unique advantage of our data is that Mayo Clinic is the only center performing ERCP in the entire county and, therefore, population based utilization and AEs of ERCP with full details of the hospitalization can be assessed.

Medical records were reviewed retrospectively by the primary author. Patient and procedural characteristics, as well as AEs within 30 days were recorded. As many as 170 variables were collected for each procedure and recorded into a database.

Primary outcomes measured were (1) utilization rates of unique ERCP procedures in the adult population (age 18 years and older) of Olmsted County from 1997-2006, and (2) the rate of unplanned admissions within 30 days following ERCP for ERCP-related AEs. Secondary outcomes included patient and procedural characteristics, predictive of having an unplanned admission within 30 days after ERCP for an ERCP-related AE.

Utilization metrics included the patients' age, sex, race, Charlson score at the time of ERCP[12], body mass index (BMI), cholecystectomy within 30 days prior to ERCP, altered anatomy (including gastrojejunostomy, Whipple anatomy, hepatico- and choledocho-jejunostomy), presence of cirrhosis, and previous history of ERCP. Indications for ERCP were then examined as biliary versus pancreatic, diagnostic versus therapeutic, and graded for

complexity using the previously published Morriston Hospital ERCP grading scale (Table IA)[13]. Diagnostic procedures had a CPT code of 43260 where no intervention was performed, other than a cholangiogram or pancreatogram; all other procedures were therapeutic. Multiple intra-procedural details, including presence of a trainee, type and amount of sedation used, and biliary and pancreatic ductal interventions were noted. Success of the procedure was recorded as the ability to cannulate the intended duct and achieve the intended therapy.

AEs recorded included unplanned admissions; sedation-related events, including pulmonary and cardiovascular events; infection; pancreatitis; bleeding; perforation; need for repeat endoscopic procedure; or mortality within 30 days. These outcomes were determined as being related to the index ERCP by author review. AEs were deemed to be definitely related, probably related, possibly related, or definitely unrelated to the index ERCP. Possibly related AEs included patients admitted with abdominal pain, but without evidence of definite pancreatitis by laboratory studies or documented cholangitis. Probably related AEs included biliary or pancreatic stent dysfunction leading to repeat the procedure within 30 days of the index procedure, but without any of the defined AEs of pancreatitis, infection, perforation, and gastrointestinal bleeding. The latter AEs were categorized as mild, moderate, and severe, according to established consensus criteria (Table IB)[6] Patients undergoing elective surgery including cholecystectomy within 30 days of ERCP were also identified.

Table IA: Morriston Hospital ERCP grading scale

Procedure	Grade
Diagnostic ERCP	I
Biliary sphincterotomy, balloon sphincteroplasty, removal of extrahepatic stones ≤ 1 cm using basket and/or balloon	II
Precut sphincterotomy, large stones removal (>1 cm), intrahepatic stone removal, mechanical lithotripsy, stricture dilatation,	III

cytology, stent insertion, and naso-biliary drain
 Sphincter of Oddi manometry, diagnostic and therapeutic ERCP IV
 after Billroth II surgery, minor papilla sphincterotomy,
 endoscopic ampullectomy, and all pancreatic duct therapeutic
 procedures. Cholangioscopy, laser lithotripsy, electrohydraulic
 lithotripsy, combined procedures (PTC and ERCP), and other
 advanced bile duct therapeutic procedures

Ragunath et al, Post Grad Med J, 2003

ERCP - endoscopic retrograde cholangiopancreatography

PTC – percutaneous transhepatic cholangiography

Table IB: Consensus criteria for ERCP complications

	Mild	Moderate	Severe
Bleeding	Clinical evidence of bleeding (ie not just endoscopic) Hemoglobin drop <3g No need for transfusion	Transfusion: 4 units or less No angiographic intervention or surgery	Transfusion: 5 units or more or intervention (angiographic or surgical)
Perforation	Possible, or only very slight leak of fluid or contrast dye Treatable by fluids and suction for 3 days or less	Any definite perforation treated medically for 4-10 days	Medical treatment for more than 10 days or intervention (percutaneous or surgical)
Pancreatitis	Clinical pancreatitis: amylase at least thrice the upper limit of normal at more than 24 hours after the procedure requiring admission or prolongation of planned admission to 2-3 days	Pancreatitis requiring hospitalization for 4-10 days	Pancreatitis requiring hospitalization for more than 10 days, or hemorrhagic pancreatitis, phlegmon, or intervention (percutaneous drainage or surgery)
Infection (cholangitis)	>38 degrees Celsius at 24-48 hours	Febrile or septic illness requiring >3 days of hospital treatment or endoscopic or percutaneous intervention	Septic shock or surgery

Cotton et al, GIE, 1991

Statistical Analysis

Univariate analyses were performed to obtain descriptive statistics for patient and procedural characteristics. Annual incidence was determined by dividing the number of ERCPs performed on the study subjects during a calendar year by the adult population of Olmsted County during that period, according to County records and normalized to 100,000 persons. To test for associations between patient and procedural characteristics and ERCP related AEs, values of these characteristics were compared between subjects who experienced ERCP-related AEs and subjects who did not by two sample t-tests for continuous variables, and chi square test for discrete variables. Multivariable logistic regression analyses were used to determine patient and procedural characteristics predictive of ERCP-related AEs. *P*-values less than 0.05 were considered statistically significant. All analyses for this study were done using SAS statistical software (SAS version 9.1 for Windows; SAS Institute Inc., Cary, North Carolina).

RESULTS

Demographic characteristics

In the 10-year period from January, 1, 1997 to December, 31, 2006, 1072 ERCPs were performed on 827 individual adult patients in Olmsted County. Patient demographic characteristics can be seen in Table II. Prior to the index cholecystectomy, 232 (28%) patients had a previous cholecystectomy; 21 (2%) patients had altered anatomy, and 20 (1.9%) were taking clopidogrel or warfarin at the time of the ERCP. There were 153 patients who had more than one ERCP during the 10-year period, and the mean number of ERCPs in these patients was 1.3.

Table II: Patient Characteristics

Age at time of ERCP (years)

mean (sd)	57.6 (19.8)
18-44 years	283 (26.4%)
45-64 years	357 (33.3%)
> 65+ years	432 (40.3%)

Gender

Female, n (%)	522 (63.1)
---------------	------------

Race

Caucasian	688 (83.2%)
African American	15 (1.8%)
Other/unknown	124 (15.0%)

Charlson index at time of ERCP

mean (sd)	3.2 (3.2)
-----------	-----------

BMI at time of ERCP

mean (sd)	28.5 (7.2)
< 25	341 (32.4%)
25-34	517 (49.1%)
35+	194 (18.4%)

ERCP – endoscopic retrograde cholangiopancreatography

BMI – body mass index

Utilization characteristics

Average utilization of ERCP was 83.1 ERCPs per 100,000 persons/year, with an increasing trend in utilization from 58.0 to 104.8 ERCPs per 100,000 persons/year over the 10-year period.

Therapeutic ERCPs increased over the same timeframe from 42.9 to 93.9 ERCPs per 100,000 persons/year (average 68.7). However, diagnostic ERCPs decreased slightly from 15.1 to 10.9 and averaged 14.4 ERCPs per 100,000 persons/year. EUS and MRCP utilization in the same population also steadily increased over this time period (Figure I).

Procedural characteristics

Procedural characteristics can be seen in Table III. Of the 1072 ERCPs performed over the 10-year period, 606(56.5%) were performed as an inpatient procedure, while 889 (82.9%) were therapeutic. The proportion of therapeutic procedures from 2002-2006 was higher than from 1997-2001 (86.6% vs 77.5%, $P=0.0001$). The difficulty grades, as defined by Morrision Hospital ERCP grading scale, were mostly Grade II(494, 46.1%) and Grade III(297, 27.7%) procedures overall; however, there was a two-fold increase in Grade IV procedures in the second five-year period, compared to the first (15.3% vs 7.2%, $P<0.0001$). ERCP was performed primarily for a biliary indication in 853 (79.6%) and a pancreatic indication in 95 (8.9%) with 122 (11.4%) for both a biliary and pancreatic indication. The commonest biliary indications included choledocholithiasis (500, 46.6%), biliary colic in the absence of documented choledocholithiasis (307, 28.6%), and relief of malignant biliary obstruction (116, 10.8%). The commonest pancreatic indications for ERCP were to determine etiology of acute pancreatitis (135, 12.6%), or recurrent acute pancreatitis (34, 3.2%), and chronic pancreatic fluid collection (18, 1.7%). Suspected sphincter of Oddi dysfunction was the indication in only (19, 1.7%) of ERCPs. A trainee was involved in 667 (62.2%) cases.

Biliary sphincterotomy was performed in 620 (57.8%) procedures; the pancreatic duct was injected in 404 (37.7%) cases and was cannulated in 255 (23.8%) procedures. Biliary stents were placed in 185 (17.3%) cases; prophylactic pancreatic stents were placed in 59 (5.5%) patients. Placement of pancreatic stents increased in the second 5-year period, compared to the first (8.1% vs 1.6%, $P<0.0001$). Ampullectomy was performed in 7 (0.7%) cases and 16 (1.5%) cases were transgastric or transduodenal débridements of pancreatic necrosis (15 of which

occurred in the second 5-year period, $P=0.0053$). Only 31 (2.9%) of ERCPs were deemed as failures as the goal of the procedure was not achieved, resulting in a 97.1% success rate. None of the patients received any prophylaxis to prevent post-ERCP pancreatitis.

Table III: Procedural Characteristics

	(%)
Cholecystectomy within 30 days prior to ERCP	113 (10.5)
Altered anatomy	21 (2.0)
Anticoagulation	20 (1.9)
Prior ERCP	277 (25.8)
Biliary indications	975 (91.0)
Cholangitis	56 (5.2)
Cholecystitis	41 (3.8)
Bleeding	4 (0.4)
Choledocholithiasis	500 (46.6)
Malignant stricture	116 (10.8)
Hilar stricture	5 (0.5)
Benign stricture	46 (4.3)
Ca pancreas	21 (2)
Papillary stenosis	8 (0.7)
Ca ampulla	14 (1.3)
Anastomotic stricture	29 (2.7)
Post cholecystectomy	69 (6.4)
Suspected SOD	19 (1.8)
PSC	21 (2)
Bile leaks	23 (2.1)
Biliary colic	307 (28.6)
Biliary dilation	27 (2.5)
Stent removal	52 (4.9)
Elevated AST and ALT	76 (7.1)
Pancreatic indications	217 (20.2)
Acute pancreatitis	135 (12.6)
Recurrent acute pancreatitis	34 (3.2)
Chronic pancreatitis	17 (1.6)
Cyst	8 (0.7)
Duct leak	9 (0.8)
Duct stricture	7 (0.7)

1		
2		
3	Acute fluid collection	7 (0.7)
4	Chronic fluid collection	18 (1.7)
5	Necrosectomy	14 (1.3)
6		
7		
8	Inpatient	606 (56.5)
9		
10	Therapeutic	889 (82.9)
11		
12		
13	Difficulty grade	
14	I	152 (14.2)
15	II	494 (46.1)
16	III	297 (27.7)
17	IV	129 (12.0)
18		
19		
20	Trainee present	667 (62.2)
21		
22	Anesthesia	
23	Conscious sedation	1030 (96.1)
24	Fentanyl	51 (4.8)
25	Versed	1028 (95.8)
26	Benadryl	6 (0.6)
27	Demerol	979 (91.2)
28	Phenergan	90 (8.4)
29	Droperidol	25 (2.3)
30	General (or propofol)	42 (3.9)
31		
32		
33		
34	Peri-ampullary diverticulum	117 (10.9)
35		
36	Biliary sphincterotomy	620 (57.8)
37		
38	Precut biliary sphincterotomy	125 (11.7)
39		
40	Biliary stent placed	185 (17.3)
41		
42		
43	Pancreatic sphincterotomy	13 (1.2)
44		
45	Pancreatic duct stent placed	59 (5.5)
46		
47		
48	Ampullectomy	7 (0.7)
49		
50	Transgastric/transduodenal drainage	16 (1.5)
51		
52		
53	Sphincterotomy bleeding noted during procedure	45 (4.2)
54		
55	ERCP – endoscopic retrograde cholangiopancreatography	
56	AST – aspartate aminotransferase	
57	ALT – alanine aminotransferase	
58		
59		
60		

Sedation

Only 42(3.9%) of procedures were done with anesthesia support. Of the remaining ERCPs done under moderate sedation, the mean dose of fentanyl was 159 ± 86 mcg (in 51 ERCPs), midazolam 6.1 ± 2.6 mg (1028 ERCPs), meperidine 97 ± 46 mg (979 ERCPs), and promethazine 21 ± 8 mg (90 ERCPs).

Outcomes

Following 1072 ERCPs in Olmsted County, over ten years, there were 273 admissions to the hospital within 30 days after 236 procedures (22% of all procedures). Table IV lists the outcomes in the study cohort. Of the 273 admissions, only 62 (22.7%) were definitely related to the index ERCP procedure, with another 2 (0.7%) probably related, and 4 (1.4%) possibly related to the procedure. Of the remaining 205 admissions unrelated to procedural AEs of the index ERCP, 79 were planned for elective surgeries, including cholecystectomy. Intraprocedural AEs were rare, with 20 (1.9%) necessitating a change in intra-procedural anesthesia; no deaths occurred during the procedure. There were 47 sphincterotomy-induced intra-procedural bleeding episodes treated with various modalities, including epinephrine injection, cautery and tamponade.

The AE rate was 5.3% including pancreatitis (26, 2.4%), infection/cholangitis (16, 1.5%), bleeding (15, 1.4%), and perforation (4, 0.37%). 53 cases were determined to be mild to moderate; however, 3 infections, all 4 perforations, and 1 bleed were considered severe. The 30-day mortality rate was 2.4%. None of the deaths were directly related to the ERCP or AEs thereof. Repeat ERCP procedures were required in 93 (8.7%) patients and 45 (4.2%) had an esophagogastroduodenoscopy (EGD) within 30 days of the index ERCP.

Table IV: Procedure Outcomes

	(%)
Success	041 (97.1)
Death	
During procedure	0 (0.0)
Within 30 days	26 (2.4)
Need for repeat procedure within 30 days	
ERCP	93 (8.7)
EGD	45 1 (4.2)
Number of readmissions within 30 days	273
Definitely related to procedure	62 (22.7)
Possibly related to procedure	6 (2.2)
Definitely not related to procedure	205 (75.1)
Surgery within 30 days	
Elective cholecystectomy	52 (4.9)
Elective Whipple	16 (5.9)
Other elective	11 (4.0)
Emergent cholecystectomy	6 (2.2)
ERCP complications requiring readmit	53 (4.9)
Pancreatitis	26 (2.4)
Mild	18
Moderate	8
Severe	0
Infection/cholangitis	16 (1.5)
Mild	6
Moderate	7
Severe	3
Bleeding	15 (1.4)
Mild	6
Moderate	8
Severe	1
Perforation	4 (0.37)
Mild	0
Moderate	0
Severe	4

Risk factors for AEs

In order to determine if there were identifiable risk factors for AEs arising from ERCP in our cohort, the relative frequency and distribution of patient and procedural characteristics were compared between patients who had a procedural AE and those who did not (Table V). Patient characteristics identified through multivariate analysis to be associated with AEs included: age less than 45 years (OR 2.23 (95% CI 1.03 – 4.84) for age <45 years vs \geq 65 years, $P=0.0498$); and BMI \geq 35 (OR 0.31 (95% CI 0.14 – 0.72) for BMI 25-34 vs \geq 35, $P=0.0024$). Procedural characteristics identified to be associated with increased risk of AEs included: patient's first ERCP (OR 2.22 (95% CI 1.04 – 4.75), $P=0.0394$); pancreatic duct cannulation (OR 2.7 (95%CI 1.4 - 5.1), $P=0.0026$); outpatient procedure (OR 5.4 (95% CI 2.6 – 11.4), $P<0.0001$); intraprocedure sphincterotomy bleeding (OR 10.0 (95% CI 3.8 – 26.1), $P<0.0001$); difficulty grade (OR 8.9 (95% CI 1.9 – 43.1) for grade 4 vs 1, $P=0.0204$).

Table V. Multivariate analysis of risk factors for post-ERCP complications

Risk factor	Odds ratio (95% CI)	P-value
Age <45 vs \geq 65	2.23 (1.03 – 4.84)	0.0498 *
Age 45-64 vs \geq 65	1.3 (0.62 – 2.72)	0.6697
Female gender	1.2 (0.61 – 2.21)	0.6412
BMI <25 vs \geq 35	0.84 (0.40 – 1.74)	0.1972
BMI 25-34 vs \geq 35	0.31 (0.14 – 0.72)	0.0024 *
No previous ERCP	2.22 (1.04 – 4.75)	0.0394 *
Outpatient ERCP	5.4 (2.6 – 11.4)	<0.0001 *
Pancreatic duct cannulation	2.7 (1.4 – 5.1)	0.0026 *

Absence of trainee	1.36	(0.72 – 2.59)	0.3487
Intraprocedure sphincterotomy bleeding	10.0	(3.8 – 26.1)	<0.0001 *
Difficulty grade 1 vs 4	0.11	(0.02 – 0.54)	0.0204 *
Difficulty grade 2 vs 4	0.45	(0.18 – 1.14)	0.9199
Difficulty grade 3 vs 4	0.94	(0.42 – 2.13)	0.0129 *

DISCUSSION

In the adult Olmsted County study population, which is considered representative of the US population, ERCP utilization rates nearly doubled over the ten-year period from January 1, 1997 to December 31, 2006 from 58.0 to 104.8 cases per 100,000 persons/year. This trend was influenced by a substantial increase in the rate of therapeutic procedures and a slight decrease in diagnostic procedures. Importantly, ERCP was performed predominantly for common ‘bread and butter’ indications including cholangitis, biliary colic, and pancreatitis. This information underscores the fact that ERCP is currently mainly a therapeutic modality, and should be available at a community-based level. Training in ERCP should be focussed on gaining expertise mainly for removal of common duct stones and relief of distal biliary obstruction. For a community based gastroenterologist, the need for more complex procedures is rare, and these procedures should be carried out at tertiary care centres.

ERCP utilization rates in Olmsted County in this study are in some ways divergent with national data. For instance, Mazen Jamal et al queried the Nationwide Inpatient Sample (NIS) data for ERCP utilization rates from 1996 to 2002[14]. They found that the rate of inpatient ERCPs dropped from 74.95/100,000 persons in 1996 to 59.70/100,000 in 2002, driven mostly by

1
2
3 a decrease in diagnostic procedures, while there was a slight concomitant increase in therapeutic
4
5
6 procedures. However, because they were using NIS sample, data are not available on outpatient
7
8 utilization of ERCP. In contrast, outpatient procedures comprised 43.5% of procedures in our
9
10 study.

11
12 Over the study period, overall utilization of EUS and MRCP have also increased in
13
14 Olmsted County. ERCP is likely now utilized almost exclusively for therapeutic purposes
15
16 because of the diagnostic abilities of EUS and MRCP, and the improvements in contrast-
17
18 enhanced CT scans. Also, increased use of EUS and MRCP might actually result in more
19
20 therapeutic ERCP as seen in our study, which contradicts popular belief that utilization of ERCP
21
22 has decreased over time with increased use of other diagnostic modalities.
23
24
25
26

27 Unplanned admissions commonly occur after ERCP (22% within 30 days), but are most
28
29 often not related to procedural AEs, which occur in 5.3% of all patients undergoing ERCP.
30
31 Unplanned admissions within 30 days after a procedure are increasingly being counted as
32
33 negative indicators of healthcare quality[15]. However, our data suggest that in the case of
34
35 ERCP, this outcome measure may not be a valid indicator of the quality of the procedure itself
36
37 and is likely related to either underlying disease, a finding of the procedure itself that leads to
38
39 elective surgery, or possibly to other comorbidities. Identification and complete capture of 30-
40
41 day admissions is a strength of our study, in comparison to past studies, where capturing remote
42
43 AEs were incomplete [6]. Because this is a population-based study, and Mayo Clinic is the only
44
45 provider for ERCP in the population, all AEs were identified.
46
47
48
49

50 Severe procedural AEs, including pancreatitis (2.4%), bleeding (1.5%), infection (1.4%),
51
52 and mortality related to the procedure (0%), were uncommon. Most AEs were mild to moderate,
53
54 and at rates similar to previously published reports[3, 6]. In a systematic review of 21 surveys of
55
56
57
58
59
60

1
2
3 ERCP, AE rates in a population of 16,855 patients were 6.85%, with pancreatitis, infection and
4 bleeding occurring in 3.5%, 1.4% and 1.3% of cases[3]; mortality rate was 0.33%. Cotton et al.
5
6 reported on 11,497 procedures at multiple centers and found a 4.0% AE rate, with rates of 2.6%
7
8 for pancreatitis and 0.3% for bleeding. Mortality rate in this cohort was 0.06%[6]. Although
9
10 2.4% of patients in our study died within 30 days of the ERCP, none of these deaths were ERCP-
11
12 related, and there were no intra- or peri-procedural deaths in our study. Because the AE rates in
13
14 our study are not appreciably different than the rates reported in the literature, it is likely that
15
16 ERCP procedures carried out at tertiary care centres are associated with low adverse event rates.
17
18
19

20
21 Numerous studies have enumerated various risk factors for AEs following ERCP[6, 8,
22
23 10, 16, 17]. Commonly accepted risk factors for any AE after ERCP include suspected sphincter
24
25 of Oddi dysfunction, cirrhosis, difficult cannulation, performance of precut sphincterotomy,
26
27 percutaneous biliary access, and lower ERCP case volumes, with young age, pancreatic duct
28
29 contrast injection and failed biliary drainage identified in some studies. In our study, younger
30
31 patient age, higher BMI, first ERCP, pancreatic duct cannulation, intra-procedural post
32
33 sphincterotomy bleeding, therapeutic procedures, and outpatient procedures were identified as
34
35 risk factors for any AE through a multivariate analysis.
36
37
38
39

40
41 Consistent with our findings, younger age has been previously shown to be a risk factor
42
43 for AEs, especially post-ERCP pancreatitis (PEP)[5, 8, 10]. Pancreatic duct cannulation is known
44
45 to be a risk-factor for development of PEP[6]. Toward the end of this study period, data emerged
46
47 supporting the use of prophylactic pancreatic duct stents to decrease the incidence of PEP and
48
49 were published. In our study period, in only 59 (5.5%) procedures, we placed a pancreatic duct
50
51 stent. Hence, our study is not able to adequately define the rate of PEP with routine placement of
52
53 prophylactic pancreatic stents.
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

One limitation of our study is that it is a retrospective review of data with its inherent biases. However, the data were manually abstracted by a single gastroenterologist from an electronic medical record, and significant adverse events and hospitalizations are not likely to have been missed. Another limitation is that even though the population studied is a county-based population, the skills of the endoscopists are at a higher level than endoscopists in smaller community hospitals. Therefore, the AE rate in this community setting could be lower than one would expect in community settings at large.

In conclusion, our study shows that utilization of ERCP at a population level continues to rise; specifically utilization of therapeutic procedures. The most common indications for ERCP remain relief of biliary colic or cholangitis, and this procedure may be carried out with moderate sedation. Adverse events of ERCP remain uncommon and deaths are rare. The study adds important epidemiologic data on trends in the utilization of ERCP, as well as population-based estimates of the risk of adverse events from ERCP that will be useful in clinical decision making and determination of resource allocation. The findings of the study may also impact ERCP training criteria.

ACKNOWLEDGEMENT

This publication was supported by NIH/NCRR CTSA Grant Number UL1 RR024150. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

REFERENCES

- [1] McCune WS, Shorb PE, Moscovitz H. Endoscopic cannulation of the ampulla of Vater: a preliminary report. *Ann Surg.* 1968 May;167(5):752-6.
- [2] Adler DG, Baron TH, Davila RE, et al. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. *Gastrointest Endosc.* 2005 Jul;62(1):1-8.
- [3] Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. *Am J Gastroenterol.* 2007 Aug;102(8):1781-8.
- [4] Bodger K, Bowering K, Sarkar S, et al. All-cause mortality after first ERCP in England: clinically guided analysis of hospital episode statistics with linkage to registry of death. *Gastrointest Endosc.* 2011 Oct;74(4):825-33.
- [5] Christensen M, Matzen P, Schulze S, et al. Complications of ERCP: a prospective study. *Gastrointest Endosc.* 2004 Nov;60(5):721-31.
- [6] Cotton PB, Garrow DA, Gallagher J, et al. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. *Gastrointest Endosc.* 2009 Jul;70(1):80-8.
- [7] Glomsaker T, Soreide K, Hoff G, et al. Contemporary use of endoscopic retrograde cholangiopancreatography (ERCP): a Norwegian prospective, multicenter study. *Scand J Gastroenterol.* 2011 Sep;46(9):1144-51.
- [8] Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. *Gastrointest Endosc.* 1998 Jul;48(1):1-10.
- [9] Sieg A, Hachmoeller-Eisenbach U, Eisenbach T. Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. *Gastrointest Endosc.* 2001 May;53(6):620-7.
- [10] Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. *The American journal of gastroenterology.* 2001 Feb;96(2):417-23.
- [11] Talley NJ, Jones M. Self-reported rectal bleeding in a United States community: prevalence, risk factors, and health care seeking. *Am J Gastroenterol.* 1998 Nov;93(11):2179-83.
- [12] Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *Journal of chronic diseases.* 1987;40(5):373-83.
- [13] Ragnath K, Thomas LA, Cheung WY, et al. Objective evaluation of ERCP procedures: a simple grading scale for evaluating technical difficulty. *Postgrad Med J.* 2003 Aug;79(934):467-70.
- [14] Mazon Jamal M, Yoon EJ, Saadi A, et al. Trends in the utilization of endoscopic retrograde cholangiopancreatography (ERCP) in the United States. *Am J Gastroenterol.* 2007 May;102(5):966-75.
- [15] Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. *N Engl J Med.* 2009 Apr 2;360(14):1418-28.
- [16] Freeman ML. Understanding risk factors and avoiding complications with endoscopic retrograde cholangiopancreatography. *Curr Gastroenterol Rep.* 2003 Apr;5(2):145-53.

1
2
3 [17] Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary
4 sphincterotomy. N Engl J Med. 1996 Sep 26;335(13):909-18.
5
6
7

8 **Figure Legends**

9
10 **Table IA.** Morriston Hospital ERCP grading scale (Ragunath et al, Post Grad Med J, 2003)
11

12 **Table IB.** Consensus criteria for ERCP complications (Cotton et al, GIE, 1991)
13

14 **Table II.** Patient Characteristics
15

16 **Table III.** Procedural Characteristics
17


18 **Table IV.** Procedure Outcomes
19

20 **Table V.** Multivariate analysis of risk factors for post-ERCP complications
21

22 **Figure I.** Utilization characteristics of ERCP, EUS, and MRCP in Olmsted County over 10-year
23 period.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1.



254x190mm (96 x 96 DPI)

Review only

STROBE STATEMENT checklist of items that should be included in reports of Observational Studies

SECTION/TOPIC	Item No.	Checklist Item	Reported on page No.
TITLE AND ABSTRACT	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	<u>2</u>
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	<u>2, 3</u>
INTRODUCTION			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	<u>4</u>
Objectives	3	State specific objectives, including any pre-specified hypotheses	<u>4, 5</u>
METHODS			
Study design	4	Present key elements of study design early in the paper	<u>5</u>
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	<u>5, 6</u>
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	<u>5, 6</u>
		(b) <i>Cohort study</i> —For match studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	<u>6, 7</u>
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	<u>6, 7</u>
Bias	9	Describe any efforts to address potential sources of bias	<u>8</u>
Study size	10	Explain how the study size was arrived at	<u>8</u>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	<u>8</u>
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	<u>7,8</u>
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
RESULTS			
Participants	13*	(a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed	<u>8</u>
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders	<u>8,9</u>
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarize follow-up time (e.g., average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	<u>10</u>
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make	<u>10</u>

Formatted: Font: Italic

Formatted: Font: Italic

		clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	(d) Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	
DISCUSSION			
Key results	18	Summarize key results with reference to study objectives	12,13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalizability	21	Discuss the generalizability (external validity) of the study results	15
OTHER INFORMATION			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>).

Information on the STROBE Initiative is available at www.strobe-statement.org.



**Endoscopic Retrograde Cholangiopancreatography –
Utilization and outcomes in a 10-year population based
cohort**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002689.R1
Article Type:	Research
Date Submitted by the Author:	22-Mar-2013
Complete List of Authors:	Coelho-Prabhu, Nayantara; Mayo Clinic, Gastroenterology and Hepatology Shah, Nilay; Mayo Clinic, Health Care Policy and Research Van Houten, Holly; Mayo Clinic, Health Care Policy and Research Kamath, Patrick; Mayo Clinic, Gastroenterology and Hepatology Baron, Todd; Mayo Clinic, Gastroenterology and Hepatology
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Evidence based practice, Gastroenterology and hepatology
Keywords:	Adult gastroenterology < GASTROENTEROLOGY, Endoscopy < GASTROENTEROLOGY, Hepatobiliary disease < GASTROENTEROLOGY, Pancreatic disease < GASTROENTEROLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Endoscopic Retrograde Cholangiopancreatography – Utilization and outcomes in a 10-year**
4 **population based cohort**
5
6

7
8 Nayantara Coelho-Prabhu, MD¹; Nilay D. Shah, PhD²; Holly Van Houten²;
9

10 Patrick S Kamath, MD¹; Todd H Baron, MD, FASGE¹
11
12

13
14
15 ¹ Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
16

17 ² Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN, USA
18
19

20
21
22 **Financial support and disclosure** – none.
23

24 **Corresponding author** – Nayantara Coelho-Prabhu, MD
25

26 200 First Street SW

27 Rochester, MN 55905, USA

28 Coelhoprabhu.nayantara@mayo.edu

29 Tel – 001-507-284-2407

30 Fax – 001-507-284-0538
31

32 Extra data is available by contacting the corresponding author.
33
34

35 **Word count** – Text – 3197
36

37 Tables – 5
38

39 Figures – 1
40
41
42
43
44

45 **Keywords:** ERCP, utilization, complications, hospitalization
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SUMMARY

Article Focus:

- Due to increasing use of quality metrics, accurate measures of utilization and procedural adverse event risks are necessary to establish benchmarks for quality, and are best determined from community-based studies.
- There are no reports of community-based utilization of ERCP in the US.
- The aims of this population-based study were to determine the utilization of ERCP including changes over time, the incidence of inpatient admissions for adverse events within 30 days of ERCP, and risk factors for procedural related adverse events.

Key Messages:

- Population utilization of ERCP in Olmsted County MN rose over the ten year period from 1997 to 2006, driven specifically by increases in therapeutic procedures. The most common indications for ERCP were therapy of choledocholithiasis and to determine etiology of acute pancreatitis.
- Admissions within 30 days after ERCP are common, but are usually unrelated. Complications of ERCP remain infrequent at 5.3% and no deaths were directly related.
- Risk factors associated with adverse events from ERCP include younger age, BMI ≥ 35 , pancreatic duct cannulation, outpatient procedures, intraprocedure sphincterotomy bleeding, difficulty grade, and patient's first ERCP.

Strengths and Limitations:

Strengths:

- Population-based epidemiologic research can be conducted in Olmsted County because medical care is virtually self-contained within the community.
- The unique advantage of our data is that Mayo Clinic is the only center performing ERCP in the entire county and, therefore, population based utilization and adverse events of ERCP with full details of procedures and subsequent hospitalizations can be assessed.

Limitations:

- The study is a retrospective review with inherent potential biases.
- The skills of the endoscopists are likely at a higher level than endoscopists in smaller community hospitals. Therefore, the adverse event rate in this community setting could be lower than one would expect in other community settings.

ABSTRACT

Objective: To determine utilization of ERCP; incidence of inpatient admissions for complications occurring within 30 days of ERCP; and risk factors for procedural related complications, in a population based study.

Design: Retrospective cohort study

Setting: Olmsted County, MN

Participants: All adult residents of Olmsted County, MN, who underwent ERCP from 1997 to 2006.

Interventions: Diagnostic and therapeutic ERCPs were assessed.

Primary and Secondary outcome measures: Patient and procedural characteristics and complications within 30 days; and rates of ERCP utilization and unplanned admissions and risk factors for admissions.

Results: In ten years, 1072 ERCPs were performed on 827 individual patients. Average utilization of ERCP was 83.1 ERCPs/100,000 persons/year, with an increase from 58.0 to 104.8 ERCPs/100,000 persons/year over time, driven by increases in therapeutic procedures. Within 30 days after 236 procedures, 62 admissions were definitely related to the index ERCP. The complication rate was 5.3%, including pancreatitis(26, 2.4%), infection/cholangitis(16, 1.5%),

1
2
3 bleeding(15, 1.4%), and perforation(4, 0.37%). 30-day mortality was 2.4%; none of which were
4
5 directly related to the ERCP or complications thereof. Risk factors identified through
6
7 multivariate analysis to be associated with adverse events included: age <45 years(p=0.0498);
8
9 BMI \geq 35(p=0.0024); pancreatic duct cannulation(p=0.0026); outpatient procedure(p<0.0001);
10
11 intraprocedure sphincterotomy bleeding(P <0.0001); difficulty grade(P =0.115); and patient's first
12
13 ERCP(P =0.0394).
14
15
16
17
18
19

20 **Limitations:** Retrospective study.
21
22
23

24 **Conclusions:** Population utilization of ERCP rose during the study period, specifically in
25
26 therapeutic procedures. Admissions within 30 days of ERCP are common, but often unrelated.
27
28 Complications of ERCP remain infrequent and deaths quite unusual.
29
30
31
32
33
34
35
36
37
38

39 **Abbreviations:**

40 AE – adverse event

41 EGD – esophagogastroduodenoscopy

42 ERCP - endoscopic retrograde cholangiopancreatography

43 EUS – endoscopic ultrasound

44 MRCP - magnetic resonance cholangiopancreatography
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BACKGROUND

Since its first description in 1968, endoscopic retrograde cholangiopancreatography (ERCP) has become an established modality for the diagnosis and treatment of pancreaticobiliary disorders^{1 2}. Over the years, ERCP has evolved from a purely diagnostic, to a mainly therapeutic procedure. Around 500,000 ERCPs are performed annually in the United States (US) with adverse event (AE) rates between 4% and 10%,³ and mortality between 0.05% and 1%⁴⁻⁷. The most common AEs following ERCP include pancreatitis, hemorrhage, and infection, which occurred in 4% to 7% of procedures^{3 6 8}. There is an increased risk of AEs after therapeutic procedures and in patients with suspected Sphincter of Oddi dysfunction⁶. Since ERCP is the endoscopic procedure with the highest cost and AE rates, diagnostic ERCP is now avoided in favor of other diagnostic modalities such as less-invasive endoscopic ultrasound (EUS) and non-invasive magnetic resonance cholangiopancreatography (MRCP)^{2 3 9}. In an era of increasing utilization of quality metrics, accurate measures of utilization rates and procedural adverse event risks are necessary to establish meaningful benchmarks for quality, and are best determined from community-based studies.

There are no reports of community-based utilization of ERCP in the US, but there are several from Europe^{8 10}. Published reports of ERCP related AEs have all been single-centered or multi-centered studies from tertiary care centers and affected by referral bias, leading to high estimates of risk that may not apply to the general population. All adverse events of procedures done at tertiary care centers may not be captured since the patients may seek care for AEs closer to their homes and thus, lost to follow-up.

The aims of this population-based study were to determine (1) the utilization of ERCP, including changes over time; (2) the incidence of inpatient admissions for AEs within 30 days of

1
2
3 ERCP; and (3) risk factors for procedural related AEs among residents of Olmsted County, MN
4
5 over a ten-year period from 1997-2006. The findings of this study are unique, as they represent
6
7 population based estimates of utilization and risks associated with ERCP and may serve as more
8
9 accurate and clinically meaningful data for clinical decision making and development of quality
10
11 benchmarks.
12
13

14 15 16 17 **METHODS**

18
19 Study Design: A retrospective cohort study was conducted with approval of the Institutional
20
21 Review Board of Mayo Clinic in compliance with federal regulations of the U.S. Department of
22
23 Health and Human Services for protection of human subjects and the Health Information
24
25 Protection and Portability Act. All patients provided consent for medical record review. Billing
26
27 records from Mayo Clinic and associated hospitals were queried for Olmsted County residents
28
29 who had undergone an ERCP during a ten-year period from January 1, 1997 to December 31,
30
31 2006. ERCPs were identified using CPT codes for ERCP, including 43260, 43261, 43262,
32
33 43263, 43264, 43265, 43267, 43268, 43269, 43271, 43272, and 47999. Utilization characteristics
34
35 for EUS were determined in the same population using codes 43232, 43238, and 43242 and for
36
37 MRCP using codes 74181, 74182, and 74183. Subjects also had to be age ≥ 18 years, live in
38
39 Olmsted County, and have valid authorization to review medical records for research purposes in
40
41 accordance with Minnesota State statutes.
42
43
44
45
46
47

48
49 Population-based epidemiologic research can be conducted in Olmsted County because
50
51 medical care is virtually self-contained within the community. Olmsted County comprises over
52
53 100,000 persons, of whom 85% are Caucasian and 50% are women; socio-demographically, the
54
55 community is similar to the US population. Over half of the county's population is seen at one of
56
57
58
59
60

1
2
3 the Mayo Clinic facilities; 95% of local residents will have had at least one medical contact with
4 a local care provider (*e.g.*, for dental X-rays, sports physical examinations, pre-employment
5 examinations, minor illness, and routine medical care) during any 4-year period¹¹. Mayo Clinic
6 has a common medical record system with its two affiliated hospitals (Saint Mary's and
7 Rochester Methodist) for 90 years. Mayo Clinic's single record system contains both inpatient
8 and outpatient data. Diagnoses and surgical procedures recorded in these records are indexed. It
9 includes diagnoses made for outpatients seen in office or clinic consultations, emergency room
10 visits, and diagnoses recorded for hospital inpatients, autopsy examinations, or on death
11 certificates. The unique advantage of our data is that Mayo Clinic is the only center performing
12 ERCP in the entire county and, therefore, population based utilization and AEs of ERCP with
13 full details of the hospitalization can be assessed.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 Medical records were reviewed retrospectively by the primary author. Patient and
30 procedural characteristics, as well as AEs within 30 days were recorded. As many as 170
31 variables were collected for each procedure and recorded into a database.
32
33
34
35

36 Primary outcomes measured were (1) utilization rates of unique ERCP procedures in the
37 adult population (age 18 years and older) of Olmsted County from 1997-2006, and (2) the rate of
38 unplanned admissions within 30 days following ERCP for ERCP-related AEs. Secondary
39 outcomes included patient and procedural characteristics, predictive of having an unplanned
40 admission within 30 days after ERCP for an ERCP-related AE.
41
42
43
44
45
46
47

48 Utilization metrics included the patients' age, sex, race, Charlson score at the time of
49 ERCP¹², body mass index (BMI), cholecystectomy within 30 days prior to ERCP, altered
50 anatomy (including gastrojejunostomy, Whipple anatomy, hepatico- and choledocho-
51 jejunostomy), presence of cirrhosis, and previous history of ERCP. Indications for ERCP were
52
53
54
55
56
57
58
59
60

1
2
3 then examined as biliary versus pancreatic, diagnostic versus therapeutic, and graded for
4
5 complexity using the previously published Morriston Hospital ERCP grading scale (Table IA)¹³.
6
7 Diagnostic procedures had a CPT code of 43260 where no intervention was performed, other
8
9 than a cholangiogram or pancreatogram; all other procedures were therapeutic. Multiple intra-
10
11 procedural details, including presence of a trainee, type and amount of sedation used, and biliary
12
13 and pancreatic ductal interventions were noted. Success of the procedure was recorded as the
14
15 ability to cannulate the intended duct and achieve the intended therapy.
16
17
18
19

20 AEs recorded included unplanned admissions; sedation-related events, including
21
22 pulmonary and cardiovascular events; infection; pancreatitis; bleeding; perforation; need for
23
24 repeat endoscopic procedure; or mortality within 30 days. These outcomes were determined as
25
26 being related to the index ERCP by author review. AEs were deemed to be definitely related,
27
28 probably related, possibly related, or definitely unrelated to the index ERCP. Possibly related
29
30 AEs included patients admitted with abdominal pain, but without evidence of definite
31
32 pancreatitis by laboratory studies or documented cholangitis. Probably related AEs included
33
34 biliary or pancreatic stent dysfunction leading to repeat the procedure within 30 days of the index
35
36 procedure, but without any of the defined AEs of pancreatitis, infection, perforation, and
37
38 gastrointestinal bleeding. The latter AEs were categorized as mild, moderate, and severe,
39
40 according to established consensus criteria (Table IB)^{6 14} Patients undergoing elective surgery
41
42 including cholecystectomy within 30 days of ERCP were also identified.
43
44
45
46
47
48
49
50

51 **Statistical Analysis**

52
53 Univariate analyses were performed to obtain descriptive statistics for patient and procedural
54
55 characteristics. Annual incidence was determined by dividing the number of ERCPs performed
56
57
58
59
60

1
2
3 on the study subjects during a calendar year by the adult population of Olmsted County during
4 that period, according to County records and normalized to 100,000 persons. To test for
5 associations between patient and procedural characteristics and ERCP related AEs, values of
6 these characteristics were compared between subjects who experienced ERCP-related AEs and
7 subjects who did not by two sample t-tests for continuous variables, and chi square test for
8 discrete variables. Multivariable logistic regression analyses were used to determine patient and
9 procedural characteristics predictive of ERCP-related AEs. *P*-values less than 0.05 were
10 considered statistically significant. All analyses for this study were done using SAS statistical
11 software (SAS version 9.1 for Windows; SAS Institute Inc., Cary, North Carolina).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 RESULTS

28 Demographic characteristics

29
30 In the 10-year period from January, 1, 1997 to December, 31, 2006, 1072 ERCPs were
31 performed on 827 individual adult patients in Olmsted County. Patient demographic
32 characteristics can be seen in Table II. Prior to the index cholecystectomy, 232 (28%) patients
33 had a previous cholecystectomy; 21 (2%) patients had altered anatomy, and 20 (1.9%) were
34 taking clopidogrel or warfarin at the time of the ERCP. There were 153 patients who had more
35 than one ERCP during the 10-year period, and the mean number of ERCPs in these patients was
36 1.3.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 Utilization characteristics

53
54 Average utilization of ERCP was 83.1 ERCPs per 100,000 persons/year, with an increasing trend
55 in utilization from 58.0 to 104.8 ERCPs per 100,000 persons/year over the 10-year period.
56
57
58
59
60

1
2
3 Therapeutic ERCPs increased over the same timeframe from 42.9 to 93.9 ERCPs per 100,000
4 persons/year (average 68.7). However, diagnostic ERCPs decreased slightly from 15.1 to 10.9
5
6 and averaged 14.4 ERCPs per 100,000 persons/year. EUS and MRCP utilization in the same
7
8 population also steadily increased over this time period (Figure I).
9
10
11

12 13 14 15 **Procedural characteristics**

16
17 Procedural characteristics can be seen in Table III. Of the 1072 ERCPs performed over the 10-
18 year period, 606(56.5%) were performed on inpatients, while 889 (82.9%) were therapeutic. The
19 proportion of therapeutic procedures from 2002-2006 was higher than from 1997-2001 (86.6%
20 vs 77.5%, $P=0.0001$). The difficulty grades, as defined by Morriston Hospital ERCP grading
21 scale, were mostly Grade II(494, 46.1%) and Grade III(297, 27.7%) procedures overall;
22 however, there was a two-fold increase in Grade IV procedures in the second five-year period,
23 compared to the first (15.3% vs 7.2%, $P<0.0001$). ERCP was performed primarily for a biliary
24 indication in 853 (79.6%) and a pancreatic indication in 95 (8.9%) with 122 (11.4%) for both a
25 biliary and pancreatic indication. The commonest biliary indications included choledocholithiasis
26 (500, 46.6%), biliary colic in the absence of documented choledocholithiasis (307, 28.6%), and
27 relief of malignant biliary obstruction (116, 10.8%). The commonest pancreatic indications for
28 ERCP were to determine etiology of acute pancreatitis (135, 12.6%), or recurrent acute
29 pancreatitis (34, 3.2%), and chronic pancreatic fluid collection (18, 1.7%). Suspected sphincter
30 of Oddi dysfunction was the indication in only (19, 1.7%) of ERCPs. A trainee was involved in
31 667 (62.2%) cases.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 Biliary sphincterotomy was performed in 620 (57.8%) procedures; the pancreatic duct
53 was injected in 404 (37.7%) cases and was cannulated in 255 (23.8%) procedures. Biliary stents
54
55
56
57
58
59
60

1
2
3 were placed in 185 (17.3%) cases; prophylactic pancreatic stents were placed in 59 (5.5%)
4
5 patients. Placement of pancreatic stents increased in the second 5-year period, compared to the
6
7 first (8.1% vs 1.6%, $P<0.0001$). Ampullectomy was performed in 7 (0.7%) cases and 16 (1.5%)
8
9 cases were transgastric or transduodenal débridements of pancreatic necrosis (15 of which
10
11 occurred in the second 5-year period, $P=0.0053$). Only 31 (2.9%) of ERCPs were deemed as
12
13 failures as the goal of the procedure was not achieved, resulting in a 97.1% success rate. None of
14
15 the patients received any prophylaxis to prevent post-ERCP pancreatitis.
16
17
18
19

20 21 22 **Sedation**

23
24 Only 42(3.9%) of procedures were done with anesthesia support. Of the remaining ERCPs done
25
26 under moderate sedation, the mean dose of fentanyl was 159 ± 86 mcg (in 51 ERCPs),
27
28 midazolam 6.1 ± 2.6 mg (1028 ERCPs), meperidine 97 ± 46 mg (979 ERCPs), and promethazine
29
30 21 ± 8 mg (90 ERCPs).
31
32
33

34 35 36 **Outcomes**

37
38 Following 1072 ERCPs in Olmsted County, over ten years, there were 273 admissions to the
39
40 hospital within 30 days after 236 procedures (22% of all procedures). Table IV lists the outcomes
41
42 in the study cohort. Of the 273 admissions, only 62 (22.7%) were definitely related to the index
43
44 ERCP procedure, with another 2 (0.7%) probably related, and 4 (1.4%) possibly related to the
45
46 procedure. Of the remaining 205 admissions unrelated to procedural AEs of the index ERCP, 79
47
48 were planned for elective surgeries, including cholecystectomy. Intraprocedural AEs were
49
50 **infrequent**, with 20 (1.9%) necessitating a change in intra-procedural anesthesia; no deaths
51
52 occurred during the procedure. There were 47 sphincterotomy-induced intra-procedural bleeding
53
54
55
56
57
58
59
60

1
2
3 episodes treated with various modalities, including epinephrine injection, cautery and
4
5
6 tamponade.
7

8 The AE rate was 5.3% including pancreatitis (26, 2.4%), infection/cholangitis (16, 1.5%),
9
10 bleeding (15, 1.4%), and perforation (4, 0.37%). 53 cases were determined to be mild to
11
12 moderate; however, 3 infections, all 4 perforations, and 1 bleed were considered severe. The 30-
13
14 day mortality rate was 2.4%. None of the deaths were directly related to the ERCP or AEs
15
16 thereof. Repeat ERCP procedures were required in 93 (8.7%) patients and 45 (4.2%) had an
17
18 esophagogastroduodenoscopy (EGD) within 30 days of the index ERCP.
19
20
21
22
23

24 **Risk factors for AEs**

25
26
27 In order to determine if there were identifiable risk factors for AEs arising from ERCP in our
28
29 cohort, the relative frequency and distribution of patient and procedural characteristics were
30
31 compared between patients who had a procedural AE and those who did not (Table V). Patient
32
33 characteristics identified through multivariate analysis to be associated with AEs included: age
34
35 less than 45 years (OR 2.23 (95% CI 1.03 – 4.84) for age <45 years vs \geq 65 years, $P=0.0498$);
36
37 and BMI \geq 35 (OR 0.31 (95% CI 0.14 – 0.72) for BMI 25-34 vs \geq 35, $P=0.0024$). Procedural
38
39 characteristics identified to be associated with increased risk of AEs included: patient's first
40
41 ERCP (OR 2.22 (95% CI 1.04 – 4.75), $P=0.0394$); pancreatic duct cannulation (OR 2.7 (95%CI
42
43 1.4 - 5.1), $P=0.0026$); outpatient procedure (OR 5.4 (95% CI 2.6 – 11.4), $P<0.0001$);
44
45
46 intraprocedure sphincterotomy bleeding (OR 10.0 (95% CI 3.8 – 26.1), $P<0.0001$); difficulty
47
48
49 grade (OR 8.9 (95% CI 1.9 – 43.1) for grade 4 vs 1, $P=0.0204$).
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

In the adult Olmsted County study population, which is considered representative of the US population, ERCP utilization rates nearly doubled over the ten-year period from January 1, 1997 to December 31, 2006 from 58.0 to 104.8 cases per 100,000 persons/year¹⁵. This trend was influenced by a substantial increase in the rate of therapeutic procedures and a slight decrease in diagnostic procedures. Importantly, ERCP was performed predominantly for common ‘bread and butter’ indications including cholangitis, biliary colic, and pancreatitis. This information underscores the fact that ERCP is currently mainly a therapeutic modality, and should be available at a community-based level. Training in ERCP should be focussed on gaining expertise mainly for removal of common duct stones and relief of distal biliary obstruction. For a community based gastroenterologist, the need for more complex procedures is rare, and these procedures should be carried out at tertiary care centres.

ERCP utilization rates in Olmsted County in this study are in some ways divergent with national data. For instance, Mazen Jamal et al queried the Nationwide Inpatient Sample (NIS) data for ERCP utilization rates from 1996 to 2002¹⁶. They found that the rate of inpatient ERCPs dropped from 74.95/100,000 persons in 1996 to 59.70/100,000 in 2002, driven mostly by a decrease in diagnostic procedures, while there was a slight concomitant increase in therapeutic procedures. However, because they were using NIS sample, data are not available on outpatient utilization of ERCP. In contrast, outpatient procedures comprised 43.5% of procedures in our study.

Over the study period, overall utilization of EUS and MRCP have also increased in Olmsted County. ERCP is likely now utilized almost exclusively for therapeutic purposes because of the diagnostic abilities of EUS and MRCP, and the improvements in contrast-

1
2
3 enhanced CT scans. Also, increased use of EUS and MRCP might actually result in more
4
5 therapeutic ERCP as seen in our study, which contradicts popular belief that utilization of ERCP
6
7 has decreased over time with increased use of other diagnostic modalities.
8
9

10
11 Unplanned admissions commonly occur after ERCP (22% within 30 days), but are most
12
13 often not related to procedural AEs, which occur in 5.3% of all patients undergoing ERCP.
14
15 Unplanned admissions within 30 days after a procedure are increasingly being counted as
16
17 negative indicators of healthcare quality¹⁷. However, our data suggest that in the case of ERCP,
18
19 this outcome measure may not be a valid indicator of the quality of the procedure itself and is
20
21 likely related to either underlying disease, a finding of the procedure itself that leads to elective
22
23 surgery, or possibly to other comorbidities. Identification and complete capture of 30-day
24
25 admissions is a strength of our study, in comparison to past studies, where capturing remote AEs
26
27 were incomplete⁶. Because this is a population-based study, and Mayo Clinic is the only
28
29 provider for ERCP in the population, all AEs were identified.
30
31
32
33

34
35 Severe procedural AEs, including pancreatitis (2.4%), bleeding (1.5%), infection (1.4%),
36
37 and mortality related to the procedure (0%), were uncommon. Most AEs were mild to moderate,
38
39 and at rates similar to previously published reports^{3 6}. In a systematic review of 21 surveys of
40
41 ERCP, AE rates in a population of 16,855 patients were 6.85%, with pancreatitis, infection and
42
43 bleeding occurring in 3.5%, 1.4% and 1.3% of cases³; mortality rate was 0.33%. Cotton et al.
44
45 reported on 11,497 procedures at multiple centers and found a 4.0% AE rate, with rates of 2.6%
46
47 for pancreatitis and 0.3% for bleeding. Mortality rate in this cohort was 0.06%⁶. Although 2.4%
48
49 of patients in our study died within 30 days of the ERCP, none of these deaths were ERCP-
50
51 related, and there were no intra- or peri-procedural deaths in our study. Because the AE rates in
52
53
54
55
56
57
58
59
60

our study are similar to the rates reported in the literature, it is likely that ERCP procedures carried out at other tertiary care centres are also associated with low adverse event rates.

Numerous studies have enumerated various risk factors for AEs following ERCP^{6 8 10 18}. Commonly accepted risk factors for any AE after ERCP include suspected sphincter of Oddi dysfunction, cirrhosis, difficult cannulation, performance of precut sphincterotomy, percutaneous biliary access, and lower ERCP case volumes, with young age, pancreatic duct contrast injection and failed biliary drainage identified in some studies. In our study, younger patient age, higher BMI, first ERCP, pancreatic duct cannulation, intra-procedural post sphincterotomy bleeding, therapeutic procedures, and outpatient procedures were identified as risk factors for any AE through a multivariate analysis.

Consistent with our findings, younger age has been previously shown to be a risk factor for AEs, especially post-ERCP pancreatitis (PEP)^{5 8 10}. Pancreatic duct cannulation is known to be a risk-factor for development of PEP⁶. Toward the end of this study period, data emerged supporting the use of prophylactic pancreatic duct stents to decrease the incidence of PEP and were published. In our study period, in only 59 (5.5%) procedures, we placed a pancreatic duct stent. Hence, our study is not able to adequately define the rate of PEP with routine placement of prophylactic pancreatic stents.

One limitation of our study is that it is a retrospective review of data with its inherent biases. However, the data were manually abstracted by a single gastroenterologist from an electronic medical record, and significant adverse events and hospitalizations are not likely to have been missed. Another limitation is that even though the population studied is a county-based population, the skills of the endoscopists are at a higher level than endoscopists in smaller community hospitals. Therefore, the AE rate in this community setting could be lower than one

1
2
3 would expect in community settings at large. Another notable limitation is that Sphincter of Oddi
4
5 dysfunction and complications of pancreatitis, diagnoses often referred to a tertiary center, were
6
7 underrepresented in our study.
8
9

10 In conclusion, our study shows that utilization of ERCP at a population level continues to
11
12 rise; specifically utilization of therapeutic procedures. The most common indications for ERCP
13
14 remain relief of biliary colic or cholangitis, and this procedure may be carried out with moderate
15
16 sedation. Adverse events of ERCP remain uncommon and deaths are infrequent. The study adds
17
18 important epidemiologic data on trends in the utilization of ERCP, as well as population-based
19
20 estimates of the risk of adverse events from ERCP that will be useful in clinical decision making
21
22 and determination of resource allocation. The findings of the study may also impact ERCP
23
24 training criteria.
25
26
27
28
29
30
31

32 **ACKNOWLEDGEMENT**

33
34 This publication was supported by NIH/NCRR CTSA Grant Number UL1 RR024150. Its
35
36 contents are solely the responsibility of the authors and do not necessarily represent the official
37
38 views of the NIH.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. McCune WS, Shorb PE, Moscovitz H. Endoscopic cannulation of the ampulla of Vater: a preliminary report. *Annals of surgery* 1968;167(5):752-6.
2. Adler DG, Baron TH, Davila RE, Egan J, Hirota WK, Leighton JA, et al. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. *Gastrointestinal endoscopy* 2005;62(1):1-8.
3. Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. *The American journal of gastroenterology* 2007;102(8):1781-8.
4. Bodger K, Bowering K, Sarkar S, Thompson E, Pearson MG. All-cause mortality after first ERCP in England: clinically guided analysis of hospital episode statistics with linkage to registry of death. *Gastrointest Endosc* 2011;74(4):825-33.
5. Christensen M, Matzen P, Schulze S, Rosenberg J. Complications of ERCP: a prospective study. *Gastrointestinal endoscopy* 2004;60(5):721-31.
6. Cotton PB, Garrow DA, Gallagher J, Romagnuolo J. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. *Gastrointestinal endoscopy* 2009;70(1):80-8.
7. Glomsaker T, Soreide K, Hoff G, Aabakken L, Soreide JA. Contemporary use of endoscopic retrograde cholangiopancreatography (ERCP): a Norwegian prospective, multicenter study. *Scand J Gastroenterol* 2011;46(9):1144-51.
8. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. *Gastrointestinal endoscopy* 1998;48(1):1-10.
9. Sieg A, Hachmoeller-Eisenbach U, Eisenbach T. Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. *Gastrointestinal endoscopy* 2001;53(6):620-7.
10. Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. *The American journal of gastroenterology* 2001;96(2):417-23.
11. Talley NJ, Jones M. Self-reported rectal bleeding in a United States community: prevalence, risk factors, and health care seeking. *The American journal of gastroenterology* 1998;93(11):2179-83.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *Journal of chronic diseases* 1987;40(5):373-83.
13. Ragnath K, Thomas LA, Cheung WY, Duane PD, Richards DG. Objective evaluation of ERCP procedures: a simple grading scale for evaluating technical difficulty. *Postgraduate medical journal* 2003;79(934):467-70.
14. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. *Gastrointestinal endoscopy* 1991;37(3):383-93.
15. St Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ, 3rd, Rocca WA. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. *Mayo Clin Proc* 2012;87(2):151-60.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16. Mazen Jamal M, Yoon EJ, Saadi A, Sy TY, Hashemzadeh M. Trends in the utilization of endoscopic retrograde cholangiopancreatography (ERCP) in the United States. *The American journal of gastroenterology* 2007;102(5):966-75.
 17. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. *The New England journal of medicine* 2009;360(14):1418-28.
 18. Freeman ML. Understanding risk factors and avoiding complications with endoscopic retrograde cholangiopancreatography. *Current gastroenterology reports* 2003;5(2):145-53.
 19. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. *The New England journal of medicine* 1996;335(13):909-18.

Figure Legends

Table IA. Morriston Hospital ERCP grading scale (Ragunath et al, Post Grad Med J, 2003)

Table IB. Consensus criteria for ERCP complications (Cotton et al, GIE, 1991)

Table II. Patient Characteristics

Table III. Procedural Characteristics

Table IV. Procedure Outcomes

Table V. Multivariate analysis of risk factors for post-ERCP complications

Figure I. Utilization characteristics of ERCP, EUS, and MRCP in Olmsted County over 10-year period.

Table IA: Morriston Hospital ERCP grading scale¹³

Procedure	Grade
Diagnostic ERCP	I
Biliary sphincterotomy, balloon sphincteroplasty, removal of extrahepatic stones ≤ 1 cm using basket and/or balloon	II
Precut sphincterotomy, large stones removal (>1 cm), intrahepatic stone removal, mechanical lithotripsy, stricture dilatation, cytology, stent insertion, and naso-biliary drain	III
Sphincter of Oddi manometry, diagnostic and therapeutic ERCP after Billroth II surgery, minor papilla sphincterotomy, endoscopic ampullectomy, and all pancreatic duct therapeutic procedures. Cholangioscopy, laser lithotripsy, electrohydraulic lithotripsy, combined procedures (PTC and ERCP), and other advanced bile duct therapeutic procedures	IV

ERCP - endoscopic retrograde cholangiopancreatography

PTC – percutaneous transhepatic cholangiography

Table IB: Consensus criteria for ERCP complications¹⁴

	Mild	Moderate	Severe
Bleeding	Clinical evidence of bleeding (ie not just endoscopic) Hemoglobin drop <3g No need for transfusion	Transfusion: 4 units or less No angiographic intervention or surgery	Transfusion: 5 units or more or intervention (angiographic or surgical)
Perforation	Possible, or only very slight leak of fluid or contrast dye Treatable by fluids and suction for 3 days or less	Any definite perforation treated medically for 4-10 days	Medical treatment for more than 10 days or intervention (percutaneous or surgical)
Pancreatitis	Clinical pancreatitis: amylase at least thrice the upper limit of normal at more than 24 hours after the procedure requiring admission or prolongation of planned admission to 2-3 days	Pancreatitis requiring hospitalization for 4-10 days	Pancreatitis requiring hospitalization for more than 10 days, or hemorrhagic pancreatitis, phlegmon, or intervention (percutaneous drainage or surgery)
Infection (cholangitis)	>38 degrees Celsius at 24-48 hours	Febrile or septic illness requiring >3 days of hospital treatment or endoscopic or percutaneous intervention	Septic shock or surgery

Table II: Patient Characteristics

Age at time of ERCP (years)	
mean (sd)	57.6 (19.8)
18-44 years	283 (26.4%)
45-64 years	357 (33.3%)
> 65+ years	432 (40.3%)
Gender	
Female, n (%)	522 (63.1)
Race	
Caucasian	688 (83.2%)
African American	15 (1.8%)
Other/unknown	124 (15.0%)
Charlson index at time of ERCP¹²	
mean (sd)	3.2 (3.2)
BMI at time of ERCP	
mean (sd)	28.5 (7.2)
< 25	341 (32.4%)
25-34	517 (49.1%)
35+	194 (18.4%)

ERCP – endoscopic retrograde cholangiopancreatography

BMI – body mass index

Table III: Procedural Characteristics

	(%)
Cholecystectomy within 30 days prior to ERCP	113 (10.5)
Altered anatomy	21 (2.0)
Anticoagulation	20 (1.9)
Prior ERCP	277 (25.8)
Biliary indications	975 (91.0)
Cholangitis	56 (5.2)
Cholecystitis	41 (3.8)
Bleeding	4 (0.4)
Choledocholithiasis	500 (46.6)
Malignant stricture	116 (10.8)
Hilar stricture	5 (0.5)
Benign stricture	46 (4.3)
Ca pancreas	21 (2)
Papillary stenosis	8 (0.7)
Ca ampulla	14 (1.3)
Anastomotic stricture	29 (2.7)
Post cholecystectomy	69 (6.4)
Suspected SOD	19 (1.8)
PSC	21 (2)
Bile leaks	23 (2.1)
Biliary colic	307 (28.6)
Biliary dilation	27 (2.5)
Stent removal	52 (4.9)
Elevated AST and ALT	76 (7.1)
Pancreatic indications	217 (20.2)
Acute pancreatitis	135 (12.6)
Recurrent acute pancreatitis	34 (3.2)
Chronic pancreatitis	17 (1.6)
Cyst	8 (0.7)
Duct leak	9 (0.8)
Duct stricture	7 (0.7)
Acute fluid collection	7 (0.7)
Chronic fluid collection	18 (1.7)
Necrosectomy	14 (1.3)
Inpatient	606 (56.5)

Therapeutic	889 (82.9)
Difficulty grade	
I	152 (14.2)
II	494 (46.1)
III	297 (27.7)
IV	129 (12.0)
Trainee present	667 (62.2)
Anesthesia	
Conscious sedation	1030 (96.1)
Fentanyl	51 (4.8)
Versed	1028 (95.8)
Benadryl	6 (0.6)
Demerol	979 (91.2)
Phenergan	90 (8.4)
Droperidol	25 (2.3)
General (or propofol)	42 (3.9)
Peri-ampullary diverticulum	117 (10.9)
Biliary sphincterotomy	620 (57.8)
Precut biliary sphincterotomy	125 (11.7)
Biliary stent placed	185 (17.3)
Pancreatic sphincterotomy	13 (1.2)
Pancreatic duct stent placed	59 (5.5)
Ampullectomy	7 (0.7)
Transgastric/transduodenal drainage	16 (1.5)
Sphincterotomy bleeding noted during procedure	45 (4.2)

ERCP – endoscopic retrograde cholangiopancreatography

AST – aspartate aminotransferase

ALT – alanine aminotransferase

Table IV: Procedure Outcomes

	(%)
Success	041 (97.1)
Death	
During procedure	0 (0.0)
Within 30 days	26 (2.4)
Need for repeat procedure within 30 days	
ERCP	93 (8.7)
EGD	45 1 (4.2)
Number of readmissions within 30 days	273
Definitely related to procedure	62 (22.7)
Possibly related to procedure	6 (2.2)
Definitely not related to procedure	205 (75.1)
Surgery within 30 days	
Elective cholecystectomy	52 (4.9)
Elective Whipple	16 (5.9)
Other elective	11 (4.0)
Emergent cholecystectomy	6 (2.2)
ERCP complications requiring readmit	53 (4.9)
Pancreatitis	26 (2.4)
Mild	18
Moderate	8
Severe	0
Infection/cholangitis	16 (1.5)
Mild	6
Moderate	7
Severe	3
Bleeding	15 (1.4)
Mild	6
Moderate	8
Severe	1
Perforation	4 (0.37)
Mild	0
Moderate	0

Severe	4
--------	---

Table V. Multivariate analysis of risk factors for post-ERCP complications

Risk factor	Odds ratio (95% CI)	P-value
Age <45 vs ≥65	2.23 (1.03 – 4.84)	0.0498 *
Age 45-64 vs ≥65	1.3 (0.62 – 2.72)	0.6697
Female gender	1.2 (0.61 – 2.21)	0.6412
BMI <25 vs ≥35	0.84 (0.40 – 1.74)	0.1972
BMI 25-34 vs ≥35	0.31 (0.14 – 0.72)	0.0024 *
No previous ERCP	2.22 (1.04 – 4.75)	0.0394 *
Outpatient ERCP	5.4 (2.6 – 11.4)	<0.0001 *
Pancreatic duct cannulation	2.7 (1.4 – 5.1)	0.0026 *
Absence of trainee	1.36 (0.72 – 2.59)	0.3487
Intraprocedure sphincterotomy bleeding	10.0 (3.8 – 26.1)	<0.0001 *
Difficulty grade 1 vs 4	0.11 (0.02 – 0.54)	0.0204 *
Difficulty grade 2 vs 4	0.45 (0.18 – 1.14)	0.9199
Difficulty grade 3 vs 4	0.94 (0.42 – 2.13)	0.0129 *

1
2
3 **Endoscopic Retrograde Cholangiopancreatography – Utilization and outcomes in a 10-year**
4 **population based cohort**
5
6

7
8 Nayantara Coelho-Prabhu, MD¹; Nilay D. Shah, PhD²; Holly Van Houten²;
9

10 Patrick S Kamath, MD¹; Todd H Baron, MD, FASGE¹
11
12

13
14
15 ¹ Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
16

17 ² Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN, USA
18
19

20
21
22 **Financial support and disclosure** – none.
23

24
25 **Corresponding author** – Nayantara Coelho-Prabhu, MD
26

27 200 First Street SW

28 Rochester, MN 55905, USA

29 Coelhoprabhu.nayantara@mayo.edu

30 Tel – 001-507-284-2407

31 Fax – 001-507-284-0538
32

33 Extra data is available by contacting the corresponding author.
34

35 **Word count** – Text – 3197
36

37 Tables – 5
38

39 Figures – 1
40
41
42
43
44

45 **Keywords:** ERCP, utilization, complications, hospitalization
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SUMMARY

Article Focus:

- Due to increasing use of quality metrics, accurate measures of utilization and procedural adverse event risks are necessary to establish benchmarks for quality, and are best determined from community-based studies.
- There are no reports of community-based utilization of ERCP in the US.
- The aims of this population-based study were to determine the utilization of ERCP including changes over time, the incidence of inpatient admissions for adverse events within 30 days of ERCP, and risk factors for procedural related adverse events.

Key Messages:

- Population utilization of ERCP in Olmsted County MN rose over the ten year period from 1997 to 2006, driven specifically by increases in therapeutic procedures. The most common indications for ERCP were therapy of choledocholithiasis and to determine etiology of acute pancreatitis.
- Admissions within 30 days after ERCP are common, but are usually unrelated. Complications of ERCP remain infrequent at 5.3% and no deaths were directly related.
- Risk factors associated with adverse events from ERCP include younger age, BMI ≥ 35 , pancreatic duct cannulation, outpatient procedures, intraprocedure sphincterotomy bleeding, difficulty grade, and patient's first ERCP.

Strengths and Limitations:

Strengths:

- Population-based epidemiologic research can be conducted in Olmsted County because medical care is virtually self-contained within the community.
- The unique advantage of our data is that Mayo Clinic is the only center performing ERCP in the entire county and, therefore, population based utilization and adverse events of ERCP with full details of procedures and subsequent hospitalizations can be assessed.

Limitations:

- The study is a retrospective review with inherent potential biases.
- The skills of the endoscopists are likely at a higher level than endoscopists in smaller community hospitals. Therefore, the adverse event rate in this community setting could be lower than one would expect in other community settings.

ABSTRACT

Objective: To determine utilization of ERCP; incidence of inpatient admissions for complications occurring within 30 days of ERCP; and risk factors for procedural related complications, in a population based study.

Design: Retrospective cohort study

Setting: Olmsted County, MN

Participants: All adult residents of Olmsted County, MN, who underwent ERCP from 1997 to 2006.

Interventions: Diagnostic and therapeutic ERCPs were assessed.

Primary and Secondary outcome measures: Patient and procedural characteristics and complications within 30 days; and rates of ERCP utilization and unplanned admissions and risk factors for admissions.

Results: In ten years, 1072 ERCPs were performed on 827 individual patients. Average utilization of ERCP was 83.1 ERCPs/100,000 persons/year, with an increase from 58.0 to 104.8 ERCPs/100,000 persons/year over time, driven by increases in therapeutic procedures. Within 30 days after 236 procedures, 62 admissions were definitely related to the index ERCP. The complication rate was 5.3%, including pancreatitis(26, 2.4%), infection/cholangitis(16, 1.5%),

1
2
3 bleeding(15, 1.4%), and perforation(4, 0.37%). 30-day mortality was 2.4%; none of which were
4
5 directly related to the ERCP or complications thereof. Risk factors identified through
6
7 multivariate analysis to be associated with adverse events included: age <45 years(p=0.0498);
8
9 BMI \geq 35(p=0.0024); pancreatic duct cannulation(p=0.0026); outpatient procedure(p<0.0001);
10
11 intraprocedure sphincterotomy bleeding(P <0.0001); difficulty grade(P =0.115); and patient's first
12
13 ERCP(P =0.0394).
14
15
16
17
18
19

20 **Limitations:** Retrospective study.
21
22
23

24 **Conclusions:** Population utilization of ERCP rose during the study period, specifically in
25
26 therapeutic procedures. Admissions within 30 days of ERCP are common, but often unrelated.
27
28 Complications of ERCP remain infrequent and deaths quite unusual.
29
30
31
32
33
34
35
36
37
38

39 **Abbreviations:**

40 AE – adverse event

41 EGD – esophagogastroduodenoscopy

42 ERCP - endoscopic retrograde cholangiopancreatography

43 EUS – endoscopic ultrasound

44 MRCP - magnetic resonance cholangiopancreatography
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BACKGROUND

Since its first description in 1968, endoscopic retrograde cholangiopancreatography (ERCP) has become an established modality for the diagnosis and treatment of pancreaticobiliary disorders^{1 2}.

Over the years, ERCP has evolved from a purely diagnostic, to a mainly therapeutic procedure. Around 500,000 ERCPs are performed annually in the United States (US) with adverse event (AE) rates between 4% and 10%,³ and mortality between 0.05% and 1%⁴⁻⁷. The most common AEs following ERCP include pancreatitis, hemorrhage, and infection, which occurred in 4% to 7% of procedures^{3 6 8}. There is an increased risk of AEs after therapeutic procedures and in patients with suspected Sphincter of Oddi dysfunction⁶. Since ERCP is the endoscopic procedure with the highest cost and AE rates, diagnostic ERCP is now avoided in favor of other diagnostic modalities such as less-invasive endoscopic ultrasound (EUS) and non-invasive magnetic resonance cholangiopancreatography (MRCP)^{2 3 9}. In an era of increasing utilization of quality metrics, accurate measures of utilization rates and procedural adverse event risks are necessary to establish meaningful benchmarks for quality, and are best determined from community-based studies.

There are no reports of community-based utilization of ERCP in the US, but there are several from Europe^{8 10}. Published reports of ERCP related AEs have all been single-centered or multi-centered studies from tertiary care centers and affected by referral bias, leading to high estimates of risk that may not apply to the general population. All adverse events of procedures done at tertiary care centers may not be captured since the patients may seek care for AEs closer to their homes and thus, lost to follow-up.

The aims of this population-based study were to determine (1) the utilization of ERCP, including changes over time; (2) the incidence of inpatient admissions for AEs within 30 days of

1
2
3 ERCP; and (3) risk factors for procedural related AEs among residents of Olmsted County, MN
4
5 over a ten-year period from 1997-2006. The findings of this study are unique, as they represent
6
7 population based estimates of utilization and risks associated with ERCP and may serve as more
8
9 accurate and clinically meaningful data for clinical decision making and development of quality
10
11 benchmarks.
12
13

14 15 16 17 **METHODS**

18
19 Study Design: A retrospective cohort study was conducted with approval of the Institutional
20
21 Review Board of Mayo Clinic in compliance with federal regulations of the U.S. Department of
22
23 Health and Human Services for protection of human subjects and the Health Information
24
25 Protection and Portability Act. All patients provided consent for medical record review. Billing
26
27 records from Mayo Clinic and associated hospitals were queried for Olmsted County residents
28
29 who had undergone an ERCP during a ten-year period from January 1, 1997 to December 31,
30
31 2006. ERCPs were identified using CPT codes for ERCP, including 43260, 43261, 43262,
32
33 43263, 43264, 43265, 43267, 43268, 43269, 43271, 43272, and 47999. Utilization characteristics
34
35 for EUS were determined in the same population using codes 43232, 43238, and 43242 and for
36
37 MRCP using codes 74181, 74182, and 74183. Subjects also had to be age ≥ 18 years, live in
38
39 Olmsted County, and have valid authorization to review medical records for research purposes in
40
41 accordance with Minnesota State statutes.
42
43
44
45
46
47

48
49 Population-based epidemiologic research can be conducted in Olmsted County because
50
51 medical care is virtually self-contained within the community. Olmsted County comprises over
52
53 100,000 persons, of whom 85% are Caucasian and 50% are women; socio-demographically, the
54
55 community is similar to the US population. Over half of the county's population is seen at one of
56
57
58
59
60

1
2
3 the Mayo Clinic facilities; 95% of local residents will have had at least one medical contact with
4 a local care provider (e.g., for dental X-rays, sports physical examinations, pre-employment
5 examinations, minor illness, and routine medical care) during any 4-year period¹¹. Mayo Clinic
6 has a common medical record system with its two affiliated hospitals (Saint Mary's and
7 Rochester Methodist) for 90 years. Mayo Clinic's single record system contains both inpatient
8 and outpatient data. Diagnoses and surgical procedures recorded in these records are indexed. It
9 includes diagnoses made for outpatients seen in office or clinic consultations, emergency room
10 visits, and diagnoses recorded for hospital inpatients, autopsy examinations, or on death
11 certificates. The unique advantage of our data is that Mayo Clinic is the only center performing
12 ERCP in the entire county and, therefore, population based utilization and AEs of ERCP with
13 full details of the hospitalization can be assessed.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 Medical records were reviewed retrospectively by the primary author. Patient and
30 procedural characteristics, as well as AEs within 30 days were recorded. As many as 170
31 variables were collected for each procedure and recorded into a database.
32
33
34
35
36

37 Primary outcomes measured were (1) utilization rates of unique ERCP procedures in the
38 adult population (age 18 years and older) of Olmsted County from 1997-2006, and (2) the rate of
39 unplanned admissions within 30 days following ERCP for ERCP-related AEs. Secondary
40 outcomes included patient and procedural characteristics, predictive of having an unplanned
41 admission within 30 days after ERCP for an ERCP-related AE.
42
43
44
45
46
47

48 Utilization metrics included the patients' age, sex, race, Charlson score at the time of
49 ERCP¹², body mass index (BMI), cholecystectomy within 30 days prior to ERCP, altered
50 anatomy (including gastrojejunostomy, Whipple anatomy, hepatico- and choledocho-
51 jejunostomy), presence of cirrhosis, and previous history of ERCP. Indications for ERCP were
52
53
54
55
56
57
58
59
60

1
2
3 then examined as biliary versus pancreatic, diagnostic versus therapeutic, and graded for
4
5 complexity using the previously published Morriston Hospital ERCP grading scale (Table IA)¹³.
6
7
8 Diagnostic procedures had a CPT code of 43260 where no intervention was performed, other
9
10 than a cholangiogram or pancreatogram; all other procedures were therapeutic. Multiple intra-
11
12 procedural details, including presence of a trainee, type and amount of sedation used, and biliary
13
14 and pancreatic ductal interventions were noted. Success of the procedure was recorded as the
15
16 ability to cannulate the intended duct and achieve the intended therapy.
17
18

19
20 AEs recorded included unplanned admissions; sedation-related events, including
21
22 pulmonary and cardiovascular events; infection; pancreatitis; bleeding; perforation; need for
23
24 repeat endoscopic procedure; or mortality within 30 days. These outcomes were determined as
25
26 being related to the index ERCP by author review. AEs were deemed to be definitely related,
27
28 probably related, possibly related, or definitely unrelated to the index ERCP. Possibly related
29
30 AEs included patients admitted with abdominal pain, but without evidence of definite
31
32 pancreatitis by laboratory studies or documented cholangitis. Probably related AEs included
33
34 biliary or pancreatic stent dysfunction leading to repeat the procedure within 30 days of the index
35
36 procedure, but without any of the defined AEs of pancreatitis, infection, perforation, and
37
38 gastrointestinal bleeding. The latter AEs were categorized as mild, moderate, and severe,
39
40 according to established consensus criteria (Table IB)^{6 14} Patients undergoing elective surgery
41
42 including cholecystectomy within 30 days of ERCP were also identified.
43
44
45
46
47
48
49

50 51 **Statistical Analysis**

52
53 Univariate analyses were performed to obtain descriptive statistics for patient and procedural
54
55 characteristics. Annual incidence was determined by dividing the number of ERCPs performed
56
57
58
59
60

1
2
3 on the study subjects during a calendar year by the adult population of Olmsted County during
4 that period, according to County records and normalized to 100,000 persons. To test for
5 associations between patient and procedural characteristics and ERCP related AEs, values of
6 these characteristics were compared between subjects who experienced ERCP-related AEs and
7 subjects who did not by two sample t-tests for continuous variables, and chi square test for
8 discrete variables. Multivariable logistic regression analyses were used to determine patient and
9 procedural characteristics predictive of ERCP-related AEs. *P*-values less than 0.05 were
10 considered statistically significant. All analyses for this study were done using SAS statistical
11 software (SAS version 9.1 for Windows; SAS Institute Inc., Cary, North Carolina).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 RESULTS

28 Demographic characteristics

29
30 In the 10-year period from January, 1, 1997 to December, 31, 2006, 1072 ERCPs were
31 performed on 827 individual adult patients in Olmsted County. Patient demographic
32 characteristics can be seen in Table II. Prior to the index cholecystectomy, 232 (28%) patients
33 had a previous cholecystectomy; 21 (2%) patients had altered anatomy, and 20 (1.9%) were
34 taking clopidogrel or warfarin at the time of the ERCP. There were 153 patients who had more
35 than one ERCP during the 10-year period, and the mean number of ERCPs in these patients was
36 1.3.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 Utilization characteristics

53 Average utilization of ERCP was 83.1 ERCPs per 100,000 persons/year, with an increasing trend
54 in utilization from 58.0 to 104.8 ERCPs per 100,000 persons/year over the 10-year period.
55
56
57
58
59
60

1
2
3 Therapeutic ERCPs increased over the same timeframe from 42.9 to 93.9 ERCPs per 100,000
4 persons/year (average 68.7). However, diagnostic ERCPs decreased slightly from 15.1 to 10.9
5
6 and averaged 14.4 ERCPs per 100,000 persons/year. EUS and MRCP utilization in the same
7
8 population also steadily increased over this time period (Figure I).
9
10
11

12 13 14 15 **Procedural characteristics**

16
17 Procedural characteristics can be seen in Table III. Of the 1072 ERCPs performed over the 10-
18 year period, 606(56.5%) were performed on inpatients, while 889 (82.9%) were therapeutic. The
19 proportion of therapeutic procedures from 2002-2006 was higher than from 1997-2001 (86.6%
20 vs 77.5%, $P=0.0001$). The difficulty grades, as defined by Morrison Hospital ERCP grading
21 scale, were mostly Grade II(494, 46.1%) and Grade III(297, 27.7%) procedures overall;
22 however, there was a two-fold increase in Grade IV procedures in the second five-year period,
23 compared to the first (15.3% vs 7.2%, $P<0.0001$). ERCP was performed primarily for a biliary
24 indication in 853 (79.6%) and a pancreatic indication in 95 (8.9%) with 122 (11.4%) for both a
25 biliary and pancreatic indication. The commonest biliary indications included choledocholithiasis
26 (500, 46.6%), biliary colic in the absence of documented choledocholithiasis (307, 28.6%), and
27 relief of malignant biliary obstruction (116, 10.8%). The commonest pancreatic indications for
28 ERCP were to determine etiology of acute pancreatitis (135, 12.6%), or recurrent acute
29 pancreatitis (34, 3.2%), and chronic pancreatic fluid collection (18, 1.7%). Suspected sphincter
30 of Oddi dysfunction was the indication in only (19, 1.7%) of ERCPs. A trainee was involved in
31 667 (62.2%) cases.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 Biliary sphincterotomy was performed in 620 (57.8%) procedures; the pancreatic duct
53 was injected in 404 (37.7%) cases and was cannulated in 255 (23.8%) procedures. Biliary stents
54
55
56
57
58
59
60

1
2
3 were placed in 185 (17.3%) cases; prophylactic pancreatic stents were placed in 59 (5.5%)
4
5 patients. Placement of pancreatic stents increased in the second 5-year period, compared to the
6
7 first (8.1% vs 1.6%, $P<0.0001$). Ampullectomy was performed in 7 (0.7%) cases and 16 (1.5%)
8
9 cases were transgastric or transduodenal débridements of pancreatic necrosis (15 of which
10
11 occurred in the second 5-year period, $P=0.0053$). Only 31 (2.9%) of ERCPs were deemed as
12
13 failures as the goal of the procedure was not achieved, resulting in a 97.1% success rate. None of
14
15 the patients received any prophylaxis to prevent post-ERCP pancreatitis.
16
17
18
19
20

21 22 **Sedation**

23
24 Only 42(3.9%) of procedures were done with anesthesia support. Of the remaining ERCPs done
25
26 under moderate sedation, the mean dose of fentanyl was 159 ± 86 mcg (in 51 ERCPs),
27
28 midazolam 6.1 ± 2.6 mg (1028 ERCPs), meperidine 97 ± 46 mg (979 ERCPs), and promethazine
29
30 21 ± 8 mg (90 ERCPs).
31
32
33
34
35

36 37 **Outcomes**

38
39 Following 1072 ERCPs in Olmsted County, over ten years, there were 273 admissions to the
40
41 hospital within 30 days after 236 procedures (22% of all procedures). Table IV lists the outcomes
42
43 in the study cohort. Of the 273 admissions, only 62 (22.7%) were definitely related to the index
44
45 ERCP procedure, with another 2 (0.7%) probably related, and 4 (1.4%) possibly related to the
46
47 procedure. Of the remaining 205 admissions unrelated to procedural AEs of the index ERCP, 79
48
49 were planned for elective surgeries, including cholecystectomy. Intra-procedural AEs were
50
51 **infrequent**, with 20 (1.9%) necessitating a change in intra-procedural anesthesia; no deaths
52
53 occurred during the procedure. There were 47 sphincterotomy-induced intra-procedural bleeding
54
55
56
57
58
59
60

1
2
3 episodes treated with various modalities, including epinephrine injection, cautery and
4
5
6 tamponade.
7

8 The AE rate was 5.3% including pancreatitis (26, 2.4%), infection/cholangitis (16, 1.5%),
9
10 bleeding (15, 1.4%), and perforation (4, 0.37%). 53 cases were determined to be mild to
11
12 moderate; however, 3 infections, all 4 perforations, and 1 bleed were considered severe. The 30-
13
14 day mortality rate was 2.4%. None of the deaths were directly related to the ERCP or AEs
15
16 thereof. Repeat ERCP procedures were required in 93 (8.7%) patients and 45 (4.2%) had an
17
18 esophagogastroduodenoscopy (EGD) within 30 days of the index ERCP.
19
20
21
22
23
24

25 **Risk factors for AEs**

26
27 In order to determine if there were identifiable risk factors for AEs arising from ERCP in our
28
29 cohort, the relative frequency and distribution of patient and procedural characteristics were
30
31 compared between patients who had a procedural AE and those who did not (Table V). Patient
32
33 characteristics identified through multivariate analysis to be associated with AEs included: age
34
35 less than 45 years (OR 2.23 (95% CI 1.03 – 4.84) for age <45 years vs ≥ 65 years, $P=0.0498$);
36
37 and BMI ≥ 35 (OR 0.31 (95% CI 0.14 – 0.72) for BMI 25-34 vs ≥ 35 , $P=0.0024$). Procedural
38
39 characteristics identified to be associated with increased risk of AEs included: patient's first
40
41 ERCP (OR 2.22 (95% CI 1.04 – 4.75), $P=0.0394$); pancreatic duct cannulation (OR 2.7 (95%CI
42
43 1.4 - 5.1), $P=0.0026$); outpatient procedure (OR 5.4 (95% CI 2.6 – 11.4), $P<0.0001$);
44
45
46 intraprocedure sphincterotomy bleeding (OR 10.0 (95% CI 3.8 – 26.1), $P<0.0001$); difficulty
47
48 grade (OR 8.9 (95% CI 1.9 – 43.1) for grade 4 vs 1, $P=0.0204$).
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

In the adult Olmsted County study population, which is considered representative of the US population, ERCP utilization rates nearly doubled over the ten-year period from January 1, 1997 to December 31, 2006 from 58.0 to 104.8 cases per 100,000 persons/year¹⁵. This trend was influenced by a substantial increase in the rate of therapeutic procedures and a slight decrease in diagnostic procedures. Importantly, ERCP was performed predominantly for common ‘bread and butter’ indications including cholangitis, biliary colic, and pancreatitis. This information underscores the fact that ERCP is currently mainly a therapeutic modality, and should be available at a community-based level. Training in ERCP should be focussed on gaining expertise mainly for removal of common duct stones and relief of distal biliary obstruction. For a community based gastroenterologist, the need for more complex procedures is rare, and these procedures should be carried out at tertiary care centres.

ERCP utilization rates in Olmsted County in this study are in some ways divergent with national data. For instance, Mazen Jamal et al queried the Nationwide Inpatient Sample (NIS) data for ERCP utilization rates from 1996 to 2002¹⁶. They found that the rate of inpatient ERCPs dropped from 74.95/100,000 persons in 1996 to 59.70/100,000 in 2002, driven mostly by a decrease in diagnostic procedures, while there was a slight concomitant increase in therapeutic procedures. However, because they were using NIS sample, data are not available on outpatient utilization of ERCP. In contrast, outpatient procedures comprised 43.5% of procedures in our study.

Over the study period, overall utilization of EUS and MRCP have also increased in Olmsted County. ERCP is likely now utilized almost exclusively for therapeutic purposes because of the diagnostic abilities of EUS and MRCP, and the improvements in contrast-

1
2
3 enhanced CT scans. Also, increased use of EUS and MRCP might actually result in more
4
5 therapeutic ERCP as seen in our study, which contradicts popular belief that utilization of ERCP
6
7 has decreased over time with increased use of other diagnostic modalities.
8
9

10
11 Unplanned admissions commonly occur after ERCP (22% within 30 days), but are most
12
13 often not related to procedural AEs, which occur in 5.3% of all patients undergoing ERCP.
14
15 Unplanned admissions within 30 days after a procedure are increasingly being counted as
16
17 negative indicators of healthcare quality¹⁷. However, our data suggest that in the case of ERCP,
18
19 this outcome measure may not be a valid indicator of the quality of the procedure itself and is
20
21 likely related to either underlying disease, a finding of the procedure itself that leads to elective
22
23 surgery, or possibly to other comorbidities. Identification and complete capture of 30-day
24
25 admissions is a strength of our study, in comparison to past studies, where capturing remote AEs
26
27 were incomplete⁶. Because this is a population-based study, and Mayo Clinic is the only
28
29 provider for ERCP in the population, all AEs were identified.
30
31
32
33

34
35 Severe procedural AEs, including pancreatitis (2.4%), bleeding (1.5%), infection (1.4%),
36
37 and mortality related to the procedure (0%), were uncommon. Most AEs were mild to moderate,
38
39 and at rates similar to previously published reports^{3 6}. In a systematic review of 21 surveys of
40
41 ERCP, AE rates in a population of 16,855 patients were 6.85%, with pancreatitis, infection and
42
43 bleeding occurring in 3.5%, 1.4% and 1.3% of cases³; mortality rate was 0.33%. Cotton et al.
44
45 reported on 11,497 procedures at multiple centers and found a 4.0% AE rate, with rates of 2.6%
46
47 for pancreatitis and 0.3% for bleeding. Mortality rate in this cohort was 0.06%⁶. Although 2.4%
48
49 of patients in our study died within 30 days of the ERCP, none of these deaths were ERCP-
50
51 related, and there were no intra- or peri-procedural deaths in our study. Because the AE rates in
52
53
54
55
56
57
58
59
60

our study are similar to the rates reported in the literature, it is likely that ERCP procedures carried out at other tertiary care centres are also associated with low adverse event rates.

Numerous studies have enumerated various risk factors for AEs following ERCP^{6 8 10 18}.¹⁹. Commonly accepted risk factors for any AE after ERCP include suspected sphincter of Oddi dysfunction, cirrhosis, difficult cannulation, performance of precut sphincterotomy, percutaneous biliary access, and lower ERCP case volumes, with young age, pancreatic duct contrast injection and failed biliary drainage identified in some studies. In our study, younger patient age, higher BMI, first ERCP, pancreatic duct cannulation, intra-procedural post sphincterotomy bleeding, therapeutic procedures, and outpatient procedures were identified as risk factors for any AE through a multivariate analysis.

Consistent with our findings, younger age has been previously shown to be a risk factor for AEs, especially post-ERCP pancreatitis (PEP)^{5 8 10}. Pancreatic duct cannulation is known to be a risk-factor for development of PEP⁶. Toward the end of this study period, data emerged supporting the use of prophylactic pancreatic duct stents to decrease the incidence of PEP and were published. In our study period, in only 59 (5.5%) procedures, we placed a pancreatic duct stent. Hence, our study is not able to adequately define the rate of PEP with routine placement of prophylactic pancreatic stents.

One limitation of our study is that it is a retrospective review of data with its inherent biases. However, the data were manually abstracted by a single gastroenterologist from an electronic medical record, and significant adverse events and hospitalizations are not likely to have been missed. Another limitation is that even though the population studied is a county-based population, the skills of the endoscopists are at a higher level than endoscopists in smaller community hospitals. Therefore, the AE rate in this community setting could be lower than one

1
2
3 would expect in community settings at large. Another notable limitation is that Sphincter of Oddi
4
5 dysfunction and complications of pancreatitis, diagnoses often referred to a tertiary center, were
6
7
8 underrepresented in our study.
9

10 In conclusion, our study shows that utilization of ERCP at a population level continues to
11
12 rise; specifically utilization of therapeutic procedures. The most common indications for ERCP
13
14 remain relief of biliary colic or cholangitis, and this procedure may be carried out with moderate
15
16 sedation. Adverse events of ERCP remain uncommon and deaths are infrequent. The study adds
17
18 important epidemiologic data on trends in the utilization of ERCP, as well as population-based
19
20 estimates of the risk of adverse events from ERCP that will be useful in clinical decision making
21
22 and determination of resource allocation. The findings of the study may also impact ERCP
23
24 training criteria.
25
26
27
28
29
30

31 32 **ACKNOWLEDGEMENT**

33
34 This publication was supported by NIH/NCRR CTSA Grant Number UL1 RR024150. Its
35
36 contents are solely the responsibility of the authors and do not necessarily represent the official
37
38 views of the NIH.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. McCune WS, Shorb PE, Moscovitz H. Endoscopic cannulation of the ampulla of Vater: a preliminary report. *Annals of surgery* 1968;167(5):752-6.
2. Adler DG, Baron TH, Davila RE, Egan J, Hirota WK, Leighton JA, et al. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. *Gastrointestinal endoscopy* 2005;62(1):1-8.
3. Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. *The American journal of gastroenterology* 2007;102(8):1781-8.
4. Bodger K, Bowering K, Sarkar S, Thompson E, Pearson MG. All-cause mortality after first ERCP in England: clinically guided analysis of hospital episode statistics with linkage to registry of death. *Gastrointest Endosc* 2011;74(4):825-33.
5. Christensen M, Matzen P, Schulze S, Rosenberg J. Complications of ERCP: a prospective study. *Gastrointestinal endoscopy* 2004;60(5):721-31.
6. Cotton PB, Garrow DA, Gallagher J, Romagnuolo J. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. *Gastrointestinal endoscopy* 2009;70(1):80-8.
7. Glomsaker T, Soreide K, Hoff G, Aabakken L, Soreide JA. Contemporary use of endoscopic retrograde cholangiopancreatography (ERCP): a Norwegian prospective, multicenter study. *Scand J Gastroenterol* 2011;46(9):1144-51.
8. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. *Gastrointestinal endoscopy* 1998;48(1):1-10.
9. Sieg A, Hachmoeller-Eisenbach U, Eisenbach T. Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. *Gastrointestinal endoscopy* 2001;53(6):620-7.
10. Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. *The American journal of gastroenterology* 2001;96(2):417-23.
11. Talley NJ, Jones M. Self-reported rectal bleeding in a United States community: prevalence, risk factors, and health care seeking. *The American journal of gastroenterology* 1998;93(11):2179-83.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *Journal of chronic diseases* 1987;40(5):373-83.
13. Ragnath K, Thomas LA, Cheung WY, Duane PD, Richards DG. Objective evaluation of ERCP procedures: a simple grading scale for evaluating technical difficulty. *Postgraduate medical journal* 2003;79(934):467-70.
14. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. *Gastrointestinal endoscopy* 1991;37(3):383-93.
15. St Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ, 3rd, Rocca WA. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. *Mayo Clin Proc* 2012;87(2):151-60.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16. Mazen Jamal M, Yoon EJ, Saadi A, Sy TY, Hashemzadeh M. Trends in the utilization of endoscopic retrograde cholangiopancreatography (ERCP) in the United States. *The American journal of gastroenterology* 2007;102(5):966-75.
 17. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. *The New England journal of medicine* 2009;360(14):1418-28.
 18. Freeman ML. Understanding risk factors and avoiding complications with endoscopic retrograde cholangiopancreatography. *Current gastroenterology reports* 2003;5(2):145-53.
 19. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. *The New England journal of medicine* 1996;335(13):909-18.

Figure Legends

Table IA. Morriston Hospital ERCP grading scale (Ragunath et al, Post Grad Med J, 2003)

Table IB. Consensus criteria for ERCP complications (Cotton et al, GIE, 1991)

Table II. Patient Characteristics

Table III. Procedural Characteristics

Table IV. Procedure Outcomes

Table V. Multivariate analysis of risk factors for post-ERCP complications

Figure I. Utilization characteristics of ERCP, EUS, and MRCP in Olmsted County over 10-year period.

Table IA: Morriston Hospital ERCP grading scale¹³

Procedure	Grade
Diagnostic ERCP	I
Biliary sphincterotomy, balloon sphincteroplasty, removal of extrahepatic stones ≤ 1 cm using basket and/or balloon	II
Precut sphincterotomy, large stones removal (>1 cm), intrahepatic stone removal, mechanical lithotripsy, stricture dilatation, cytology, stent insertion, and naso-biliary drain	III
Sphincter of Oddi manometry, diagnostic and therapeutic ERCP after Billroth II surgery, minor papilla sphincterotomy, endoscopic ampullectomy, and all pancreatic duct therapeutic procedures. Cholangioscopy, laser lithotripsy, electrohydraulic lithotripsy, combined procedures (PTC and ERCP), and other advanced bile duct therapeutic procedures	IV

ERCP - endoscopic retrograde cholangiopancreatography

PTC – percutaneous transhepatic cholangiography

Table IB: Consensus criteria for ERCP complications ¹⁴

	Mild	Moderate	Severe
Bleeding	Clinical evidence of bleeding (ie not just endoscopic) Hemoglobin drop <3g No need for transfusion	Transfusion: 4 units or less No angiographic intervention or surgery	Transfusion: 5 units or more or intervention (angiographic or surgical)
Perforation	Possible, or only very slight leak of fluid or contrast dye Treatable by fluids and suction for 3 days or less	Any definite perforation treated medically for 4-10 days	Medical treatment for more than 10 days or intervention (percutaneous or surgical)
Pancreatitis	Clinical pancreatitis: amylase at least thrice the upper limit of normal at more than 24 hours after the procedure requiring admission or prolongation of planned admission to 2-3 days	Pancreatitis requiring hospitalization for 4-10 days	Pancreatitis requiring hospitalization for more than 10 days, or hemorrhagic pancreatitis, phlegmon, or intervention (percutaneous drainage or surgery)
Infection (cholangitis)	>38 degrees Celsius at 24-48 hours	Febrile or septic illness requiring >3 days of hospital treatment or endoscopic or percutaneous intervention	Septic shock or surgery

Table II: Patient Characteristics

Age at time of ERCP (years)	
mean (sd)	57.6 (19.8)
18-44 years	283 (26.4%)
45-64 years	357 (33.3%)
> 65+ years	432 (40.3%)
Gender	
Female, n (%)	522 (63.1)
Race	
Caucasian	688 (83.2%)
African American	15 (1.8%)
Other/unknown	124 (15.0%)
Charlson index at time of ERCP¹²	
mean (sd)	3.2 (3.2)
BMI at time of ERCP	
mean (sd)	28.5 (7.2)
< 25	341 (32.4%)
25-34	517 (49.1%)
35+	194 (18.4%)

ERCP – endoscopic retrograde cholangiopancreatography

BMI – body mass index

Table III: Procedural Characteristics

	(%)
Cholecystectomy within 30 days prior to ERCP	113 (10.5)
Altered anatomy	21 (2.0)
Anticoagulation	20 (1.9)
Prior ERCP	277 (25.8)
Biliary indications	975 (91.0)
Cholangitis	56 (5.2)
Cholecystitis	41 (3.8)
Bleeding	4 (0.4)
Choledocholithiasis	500 (46.6)
Malignant stricture	116 (10.8)
Hilar stricture	5 (0.5)
Benign stricture	46 (4.3)
Ca pancreas	21 (2)
Papillary stenosis	8 (0.7)
Ca ampulla	14 (1.3)
Anastomotic stricture	29 (2.7)
Post cholecystectomy	69 (6.4)
Suspected SOD	19 (1.8)
PSC	21 (2)
Bile leaks	23 (2.1)
Biliary colic	307 (28.6)
Biliary dilation	27 (2.5)
Stent removal	52 (4.9)
Elevated AST and ALT	76 (7.1)
Pancreatic indications	217 (20.2)
Acute pancreatitis	135 (12.6)
Recurrent acute pancreatitis	34 (3.2)
Chronic pancreatitis	17 (1.6)
Cyst	8 (0.7)
Duct leak	9 (0.8)
Duct stricture	7 (0.7)
Acute fluid collection	7 (0.7)
Chronic fluid collection	18 (1.7)
Necrosectomy	14 (1.3)
Inpatient	606 (56.5)

Therapeutic	889 (82.9)
Difficulty grade	
I	152 (14.2)
II	494 (46.1)
III	297 (27.7)
IV	129 (12.0)
Trainee present	667 (62.2)
Anesthesia	
Conscious sedation	1030 (96.1)
Fentanyl	51 (4.8)
Versed	1028 (95.8)
Benadryl	6 (0.6)
Demerol	979 (91.2)
Phenergan	90 (8.4)
Droperidol	25 (2.3)
General (or propofol)	42 (3.9)
Peri-ampullary diverticulum	117 (10.9)
Biliary sphincterotomy	620 (57.8)
Precut biliary sphincterotomy	125 (11.7)
Biliary stent placed	185 (17.3)
Pancreatic sphincterotomy	13 (1.2)
Pancreatic duct stent placed	59 (5.5)
Ampullectomy	7 (0.7)
Transgastric/transduodenal drainage	16 (1.5)
Sphincterotomy bleeding noted during procedure	45 (4.2)

ERCP – endoscopic retrograde cholangiopancreatography

AST – aspartate aminotransferase

ALT – alanine aminotransferase

Table IV: Procedure Outcomes

	(%)
Success	041 (97.1)
Death	
During procedure	0 (0.0)
Within 30 days	26 (2.4)
Need for repeat procedure within 30 days	
ERCP	93 (8.7)
EGD	45 1 (4.2)
Number of readmissions within 30 days	273
Definitely related to procedure	62 (22.7)
Possibly related to procedure	6 (2.2)
Definitely not related to procedure	205 (75.1)
Surgery within 30 days	
Elective cholecystectomy	52 (4.9)
Elective Whipple	16 (5.9)
Other elective	11 (4.0)
Emergent cholecystectomy	6 (2.2)
ERCP complications requiring readmit	53 (4.9)
Pancreatitis	26 (2.4)
Mild	18
Moderate	8
Severe	0
Infection/cholangitis	16 (1.5)
Mild	6
Moderate	7
Severe	3
Bleeding	15 (1.4)
Mild	6
Moderate	8
Severe	1
Perforation	4 (0.37)
Mild	0
Moderate	0


Severe	4
--------	---

Table V. Multivariate analysis of risk factors for post-ERCP complications

Risk factor	Odds ratio (95% CI)	P-value
Age <45 vs ≥65	2.23 (1.03 – 4.84)	0.0498 *
Age 45-64 vs ≥65	1.3 (0.62 – 2.72)	0.6697
Female gender	1.2 (0.61 – 2.21)	0.6412
BMI <25 vs ≥35	0.84 (0.40 – 1.74)	0.1972
BMI 25-34 vs ≥35	0.31 (0.14 – 0.72)	0.0024 *
No previous ERCP	2.22 (1.04 – 4.75)	0.0394 *
Outpatient ERCP	5.4 (2.6 – 11.4)	<0.0001 *
Pancreatic duct cannulation	2.7 (1.4 – 5.1)	0.0026 *
Absence of trainee	1.36 (0.72 – 2.59)	0.3487
Intraprocedure sphincterotomy bleeding	10.0 (3.8 – 26.1)	<0.0001 *
Difficulty grade 1 vs 4	0.11 (0.02 – 0.54)	0.0204 *
Difficulty grade 2 vs 4	0.45 (0.18 – 1.14)	0.9199
Difficulty grade 3 vs 4	0.94 (0.42 – 2.13)	0.0129 *

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1.



254x190mm (96 x 96 DPI)

STROBE STATEMENT checklist of items that should be included in reports of Observational Studies

SECTION/TOPIC	Item No.	Checklist Item	Reported on page No.
TITLE AND ABSTRACT	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	<u>2</u>
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	<u>2, 3</u>
INTRODUCTION			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	<u>4</u>
Objectives	3	State specific objectives, including any pre-specified hypotheses	<u>4, 5</u>
METHODS			
Study design	4	Present key elements of study design early in the paper	<u>5</u>
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	<u>5, 6</u>
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	<u>5, 6</u>
		(b) <i>Cohort study</i> —For match studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	<u>6, 7</u>
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	<u>6, 7</u>
Bias	9	Describe any efforts to address potential sources of bias	<u>8</u>
Study size	10	Explain how the study size was arrived at	<u>8</u>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	<u>8</u>
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	<u>7,8</u>
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
RESULTS			
Participants	13*	(a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed	<u>8</u>
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders	<u>8,9</u>
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarize follow-up time (e.g., average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	<u>10</u>
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make	<u>10</u>

Formatted: Font: Italic

Formatted: Font: Italic

		clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	(d) Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	
DISCUSSION			
Key results	18	Summarize key results with reference to study objectives	12,13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalizability	21	Discuss the generalizability (external validity) of the study results	15
OTHER INFORMATION			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>).

Information on the STROBE Initiative is available at www.strobe-statement.org.



**Endoscopic Retrograde Cholangiopancreatography –
Utilization and outcomes in a 10-year population based
cohort**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002689.R2
Article Type:	Research
Date Submitted by the Author:	25-Apr-2013
Complete List of Authors:	Coelho-Prabhu, Nayantara; Mayo Clinic, Gastroenterology and Hepatology Shah, Nilay; Mayo Clinic, Health Care Policy and Research Van Houten, Holly; Mayo Clinic, Health Care Policy and Research Kamath, Patrick; Mayo Clinic, Gastroenterology and Hepatology Baron, Todd; Mayo Clinic, Gastroenterology and Hepatology
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	Evidence based practice, Surgery
Keywords:	Adult gastroenterology < GASTROENTEROLOGY, Endoscopy < GASTROENTEROLOGY, Hepatobiliary disease < GASTROENTEROLOGY, Pancreatic disease < GASTROENTEROLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Endoscopic Retrograde Cholangiopancreatography – Utilization and outcomes in a 10-year**
4 **population based cohort**
5
6

7
8 Nayantara Coelho-Prabhu, MD¹; Nilay D. Shah, PhD²; Holly Van Houten²;
9

10 Patrick S Kamath, MD¹; Todd H Baron, MD, FASGE¹
11
12

13
14
15 ¹ Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
16

17 ² Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN, USA
18
19

20
21
22 **Financial support and disclosure** – none.
23

24
25 **Corresponding author** – Nayantara Coelho-Prabhu, MD
26 200 First Street SW
27 Rochester, MN 55905, USA
28 Coelhoprabhu.nayantara@mayo.edu
29 Tel – 001-507-284-2407
30 Fax – 001-507-284-0538
31

32 Extra data is available by contacting the corresponding author.
33
34

35 **Word count** – Text – 3197
36

37 Tables – 5
38

39 Figures – 1
40
41
42
43
44

45 **Keywords:** ERCP, utilization, complications, hospitalization
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SUMMARY

Article Focus:

- Due to increasing use of quality metrics, accurate measures of utilization and procedural adverse event risks are necessary to establish benchmarks for quality, and are best determined from community-based studies.
- There are no reports of community-based utilization of ERCP in the US.
- The aims of this population-based study were to determine the utilization of ERCP including changes over time, the incidence of inpatient admissions for adverse events within 30 days of ERCP, and risk factors for procedural related adverse events.

Key Messages:

- Population utilization of ERCP in Olmsted County MN rose over the ten year period from 1997 to 2006, driven specifically by increases in therapeutic procedures. The most common indications for ERCP were therapy of choledocholithiasis and to determine etiology of acute pancreatitis.
- Admissions within 30 days after ERCP are common, but are usually unrelated. Complications of ERCP remain infrequent at 5.3% and no deaths were directly related.
- Risk factors associated with adverse events from ERCP include younger age, BMI ≥ 35 , pancreatic duct cannulation, outpatient procedures, intraprocedure sphincterotomy bleeding, difficulty grade, and patient's first ERCP.

Strengths and Limitations:

Strengths:

- Population-based epidemiologic research can be conducted in Olmsted County because medical care is virtually self-contained within the community.
- The unique advantage of our data is that Mayo Clinic is the only center performing ERCP in the entire county and, therefore, population based utilization and adverse events of ERCP with full details of procedures and subsequent hospitalizations can be assessed.

Limitations:

- The study is a retrospective review with inherent potential biases.
- The skills of the endoscopists are likely at a higher level than endoscopists in smaller community hospitals. Therefore, the adverse event rate in this community setting could be lower than one would expect in other community settings.

ABSTRACT

Objective: To determine utilization of ERCP; incidence of inpatient admissions for complications occurring within 30 days of ERCP; and risk factors for procedural related complications, in a population based study.

Design: Retrospective cohort study

Setting: Olmsted County, MN

Participants: All adult residents of Olmsted County, MN, who underwent ERCP from 1997 to 2006.

Interventions: Diagnostic and therapeutic ERCPs were assessed.

Primary and Secondary outcome measures: Patient and procedural characteristics and complications within 30 days; and rates of ERCP utilization and unplanned admissions and risk factors for admissions.

Results: In ten years, 1072 ERCPs were performed on 827 individual patients. Average utilization of ERCP was 83.1 ERCPs/100,000 persons/year, with an increase from 58.0 to 104.8 ERCPs/100,000 persons/year over time, driven by increases in therapeutic procedures. Within 30 days after 236 procedures, 62 admissions were definitely related to the index ERCP. The complication rate was 5.3%, including pancreatitis(26, 2.4%), infection/cholangitis(16, 1.5%),

1
2
3 bleeding(15, 1.4%), and perforation(4, 0.37%). 30-day mortality was 2.4%; none of which were
4
5 directly related to the ERCP or complications thereof. Risk factors identified through
6
7 multivariate analysis to be associated with adverse events included: age <45 years(p=0.0498);
8
9 BMI \geq 35(p=0.0024); pancreatic duct cannulation(p=0.0026); outpatient procedure(p<0.0001);
10
11 intraprocedure sphincterotomy bleeding(P <0.0001); difficulty grade(P =0.115); and patient's first
12
13 ERCP(P =0.0394).
14
15
16
17
18
19

20 **Limitations:** Retrospective study.
21
22
23

24 **Conclusions:** Population utilization of ERCP rose during the study period, specifically in
25
26 therapeutic procedures. Admissions within 30 days of ERCP are common, but often unrelated.
27
28 Complications of ERCP remain infrequent and deaths quite unusual.
29
30
31
32
33
34
35
36
37
38

39 **Abbreviations:**

40 AE – adverse event

41 EGD – esophagogastroduodenoscopy

42 ERCP - endoscopic retrograde cholangiopancreatography

43 EUS – endoscopic ultrasound

44 MRCP - magnetic resonance cholangiopancreatography
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BACKGROUND

Since its first description in 1968, endoscopic retrograde cholangiopancreatography (ERCP) has become an established modality for the diagnosis and treatment of pancreaticobiliary disorders^{1 2}. Over the years, ERCP has evolved from a purely diagnostic, to a mainly therapeutic procedure. Around 500,000 ERCPs are performed annually in the United States (US) with adverse event (AE) rates between 4% and 10%,³ and mortality between 0.05% and 1%⁴⁻⁷. The most common AEs following ERCP include pancreatitis, hemorrhage, and infection, which occurred in 4% to 7% of procedures^{3 6 8}. There is an increased risk of AEs after therapeutic procedures and in patients with suspected Sphincter of Oddi dysfunction⁶. Since ERCP is the endoscopic procedure with the highest cost and AE rates, diagnostic ERCP is now avoided in favor of other diagnostic modalities such as less-invasive endoscopic ultrasound (EUS) and non-invasive magnetic resonance cholangiopancreatography (MRCP)^{2 3 9}. In an era of increasing utilization of quality metrics, accurate measures of utilization rates and procedural adverse event risks are necessary to establish meaningful benchmarks for quality, and are best determined from community-based studies.

There are no reports of community-based utilization of ERCP in the US, but there are several from Europe^{8 10}. Published reports of ERCP related AEs have all been single-centered or multi-centered studies from tertiary care centers and affected by referral bias, leading to high estimates of risk that may not apply to the general population. All adverse events of procedures done at tertiary care centers may not be captured since the patients may seek care for AEs closer to their homes and thus, lost to follow-up.

The aims of this population-based study were to determine (1) the utilization of ERCP, including changes over time; (2) the incidence of inpatient admissions for AEs within 30 days of

1
2
3 ERCP; and (3) risk factors for procedural related AEs among residents of Olmsted County, MN
4
5 over a ten-year period from 1997-2006. The findings of this study are unique, as they represent
6
7 population based estimates of utilization and risks associated with ERCP and may serve as more
8
9 accurate and clinically meaningful data for clinical decision making and development of quality
10
11 benchmarks.
12
13

14 15 16 17 **METHODS**

18
19 Study Design: A retrospective cohort study was conducted with approval of the Institutional
20
21 Review Board of Mayo Clinic in compliance with federal regulations of the U.S. Department of
22
23 Health and Human Services for protection of human subjects and the Health Information
24
25 Protection and Portability Act. All patients provided consent for medical record review. Billing
26
27 records from Mayo Clinic and associated hospitals were queried for Olmsted County residents
28
29 who had undergone an ERCP during a ten-year period from January 1, 1997 to December 31,
30
31 2006. ERCPs were identified using CPT codes for ERCP, including 43260, 43261, 43262,
32
33 43263, 43264, 43265, 43267, 43268, 43269, 43271, 43272, and 47999. Utilization characteristics
34
35 for EUS were determined in the same population using codes 43232, 43238, and 43242 and for
36
37 MRCP using codes 74181, 74182, and 74183. Subjects also had to be age ≥ 18 years, live in
38
39 Olmsted County, and have valid authorization to review medical records for research purposes in
40
41 accordance with Minnesota State statutes.
42
43
44
45
46
47

48
49 Population-based epidemiologic research can be conducted in Olmsted County because
50
51 medical care is virtually self-contained within the community. Olmsted County comprises over
52
53 100,000 persons, of whom 85% are Caucasian and 50% are women; socio-demographically, the
54
55 community is similar to the US population. Over half of the county's population is seen at one of
56
57
58
59
60

1
2
3 the Mayo Clinic facilities; 95% of local residents will have had at least one medical contact with
4 a local care provider (*e.g.*, for dental X-rays, sports physical examinations, pre-employment
5 examinations, minor illness, and routine medical care) during any 4-year period¹¹. Mayo Clinic
6
7
8 has a common medical record system with its two affiliated hospitals (Saint Mary's and
9
10
11
12 Rochester Methodist) for 90 years. Mayo Clinic's single record system contains both inpatient
13
14
15 and outpatient data. Diagnoses and surgical procedures recorded in these records are indexed. It
16
17
18 includes diagnoses made for outpatients seen in office or clinic consultations, emergency room
19
20
21 visits, and diagnoses recorded for hospital inpatients, autopsy examinations, or on death
22
23
24 certificates. The unique advantage of our data is that Mayo Clinic is the only center performing
25
26
27 ERCP in the entire county and, therefore, population based utilization and AEs of ERCP with
28
29
30 full details of the hospitalization can be assessed.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Medical records were reviewed retrospectively by the primary author. Patient and procedural characteristics, as well as AEs within 30 days were recorded. As many as 170 variables were collected for each procedure and recorded into a database.

Primary outcomes measured were (1) utilization rates of unique ERCP procedures in the adult population (age 18 years and older) of Olmsted County from 1997-2006, and (2) the rate of unplanned admissions within 30 days following ERCP for ERCP-related AEs. Secondary outcomes included patient and procedural characteristics, predictive of having an unplanned admission within 30 days after ERCP for an ERCP-related AE.

Utilization metrics included the patients' age, sex, race, Charlson score at the time of ERCP¹², body mass index (BMI), cholecystectomy within 30 days prior to ERCP, altered anatomy (including gastrojejunostomy, Whipple anatomy, hepatico- and choledocho-jejunostomy), presence of cirrhosis, and previous history of ERCP. Indications for ERCP were

1
2
3 then examined as biliary versus pancreatic, diagnostic versus therapeutic, and graded for
4
5 complexity using the previously published Morriston Hospital ERCP grading scale (Table IA)¹³.
6
7 Diagnostic procedures had a CPT code of 43260 where no intervention was performed, other
8
9 than a cholangiogram or pancreatogram; all other procedures were therapeutic. Multiple intra-
10
11 procedural details, including presence of a trainee, type and amount of sedation used, and biliary
12
13 and pancreatic ductal interventions were noted. Success of the procedure was recorded as the
14
15 ability to cannulate the intended duct and achieve the intended therapy.
16
17
18
19

20 AEs recorded included unplanned admissions; sedation-related events, including
21
22 pulmonary and cardiovascular events; infection; pancreatitis; bleeding; perforation; need for
23
24 repeat endoscopic procedure; or mortality within 30 days. These outcomes were determined as
25
26 being related to the index ERCP by author review. AEs were deemed to be definitely related,
27
28 probably related, possibly related, or definitely unrelated to the index ERCP. Possibly related
29
30 AEs included patients admitted with abdominal pain, but without evidence of definite
31
32 pancreatitis by laboratory studies or documented cholangitis. Probably related AEs included
33
34 biliary or pancreatic stent dysfunction leading to repeat the procedure within 30 days of the index
35
36 procedure, but without any of the defined AEs of pancreatitis, infection, perforation, and
37
38 gastrointestinal bleeding. The latter AEs were categorized as mild, moderate, and severe,
39
40 according to established consensus criteria (Table IB)^{6 14} Patients undergoing elective surgery
41
42 including cholecystectomy within 30 days of ERCP were also identified.
43
44
45
46
47
48
49
50

51 **Statistical Analysis**

52
53 Univariate analyses were performed to obtain descriptive statistics for patient and procedural
54
55 characteristics. Annual incidence was determined by dividing the number of ERCPs performed
56
57
58
59
60

1
2
3 on the study subjects during a calendar year by the adult population of Olmsted County during
4 that period, according to County records and normalized to 100,000 persons. To test for
5 associations between patient and procedural characteristics and ERCP related AEs, values of
6 these characteristics were compared between subjects who experienced ERCP-related AEs and
7 subjects who did not by two sample t-tests for continuous variables, and chi square test for
8 discrete variables. Multivariable logistic regression analyses were used to determine patient and
9 procedural characteristics predictive of ERCP-related AEs. *P*-values less than 0.05 were
10 considered statistically significant. All analyses for this study were done using SAS statistical
11 software (SAS version 9.1 for Windows; SAS Institute Inc., Cary, North Carolina).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 RESULTS

28 Demographic characteristics

29
30 In the 10-year period from January, 1, 1997 to December, 31, 2006, 1072 ERCPs were
31 performed on 827 individual adult residents of Olmsted County. The total number of ERCPs
32 done during this time period was 13056 including the non-residents of Olmsted County. Patient
33 demographic characteristics can be seen in Table II. Prior to the index cholecystectomy, 232
34 (28%) patients had a previous cholecystectomy; 21 (2%) patients had altered anatomy, and 20
35 (1.9%) were taking clopidogrel or warfarin at the time of the ERCP. There were 153 patients
36 who had more than one ERCP during the 10-year period, and the mean number of ERCPs in
37 these patients was 1.3.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 Utilization characteristics

1
2
3 Average utilization of ERCP was 83.1 ERCPs per 100,000 persons/year, with an increasing trend
4
5 in utilization from 58.0 to 104.8 ERCPs per 100,000 persons/year over the 10-year period.
6
7
8 Therapeutic ERCPs increased over the same timeframe from 42.9 to 93.9 ERCPs per 100,000
9
10 persons/year (average 68.7). However, diagnostic ERCPs decreased slightly from 15.1 to 10.9
11
12 and averaged 14.4 ERCPs per 100,000 persons/year. EUS and MRCP utilization in the same
13
14 population also steadily increased over this time period (Figure I).
15
16
17
18
19

20 **Procedural characteristics**

21
22 Procedural characteristics can be seen in Table III. Of the 1072 ERCPs performed over the 10-
23
24 year period, 606(56.5%) were performed on inpatients, while 889 (82.9%) were therapeutic. The
25
26 proportion of therapeutic procedures from 2002-2006 was higher than from 1997-2001 (86.6%
27
28 vs 77.5%, $P=0.0001$). The difficulty grades, as defined by Morrison Hospital ERCP grading
29
30 scale, were mostly Grade II(494, 46.1%) and Grade III(297, 27.7%) procedures overall;
31
32 however, there was a two-fold increase in Grade IV procedures in the second five-year period,
33
34 compared to the first (15.3% vs 7.2%, $P<0.0001$). ERCP was performed primarily for a biliary
35
36 indication in 853 (79.6%) and a pancreatic indication in 95 (8.9%) with 122 (11.4%) for both a
37
38 biliary and pancreatic indication. The commonest biliary indications included choledocholithiasis
39
40 (500, 46.6%), biliary colic in the absence of documented choledocholithiasis (307, 28.6%), and
41
42 relief of malignant biliary obstruction (116, 10.8%). The commonest pancreatic indications for
43
44 ERCP were to determine etiology of acute pancreatitis (135, 12.6%), or recurrent acute
45
46 pancreatitis (34, 3.2%), and chronic pancreatic fluid collection (18, 1.7%). Suspected sphincter
47
48 of Oddi dysfunction was the indication in only (19, 1.7%) of ERCPs. A trainee was involved in
49
50 667 (62.2%) cases.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Biliary sphincterotomy was performed in 620 (57.8%) procedures; the pancreatic duct was injected in 404 (37.7%) cases and was cannulated in 255 (23.8%) procedures. In some cases, the intent was to cannulate the bile duct, but pancreatic duct injection occurred during the process. Biliary stents were placed in 185 (17.3%) cases; prophylactic pancreatic stents were placed in 59 (5.5%) patients. Placement of pancreatic stents increased in the second 5-year period, compared to the first (8.1% vs 1.6%, $P<0.0001$). Ampullectomy was performed in 7 (0.7%) cases and 16 (1.5%) cases were transgastric or transduodenal débridements of pancreatic necrosis (15 of which occurred in the second 5-year period, $P=0.0053$). Only 31 (2.9%) of ERCPs were deemed as failures as the goal of the procedure was not achieved, resulting in a 97.1% success rate. None of the patients received any prophylaxis to prevent post-ERCP pancreatitis.

Sedation

Only 42(3.9%) of procedures were done with anesthesia support. Of the remaining ERCPs done under moderate sedation, the mean dose of fentanyl was $159 \pm 86\text{mcg}$ (in 51 ERCPs), midazolam $6.1 \pm 2.6\text{mg}$ (1028 ERCPs), meperidine $97 \pm 46\text{mg}$ (979 ERCPs), and promethazine $21 \pm 8\text{mg}$ (90 ERCPs).

Outcomes

Following 1072 ERCPs in Olmsted County, over ten years, there were 273 admissions to the hospital within 30 days after 236 procedures (22% of all procedures). Table IV lists the outcomes in the study cohort. Of the 273 admissions, only 62 (22.7%) were definitely related to the index ERCP procedure, with another 2 (0.7%) probably related, and 4 (1.4%) possibly related to the

1
2
3 procedure. Of the remaining 205 admissions unrelated to procedural AEs of the index ERCP, 79
4
5 were planned for elective surgeries, including cholecystectomy. Intra-procedural AEs were
6
7 infrequent, with 20 (1.9%) necessitating a change in intra-procedural anesthesia; no deaths
8
9 occurred during the procedure. There were 47 sphincterotomy-induced intra-procedural bleeding
10
11 episodes treated with various modalities, including epinephrine injection, cautery and
12
13 tamponade.
14

15
16
17 The AE rate was 5.3% including pancreatitis (26, 2.4%), infection/cholangitis (16, 1.5%),
18
19 bleeding (15, 1.4%), and perforation (4, 0.37%). 53 cases were determined to be mild to
20
21 moderate; however, 3 infections, all 4 perforations, and 1 bleed were considered severe. The 30-
22
23 day mortality rate was 2.4%; 69% of deaths were due to underlying malignancy, 12% were due
24
25 to infections unrelated to the ERCP, and 19% were due to other causes including stroke,
26
27 respiratory failure, and dementia. None of the deaths were directly related to the ERCP or AEs
28
29 thereof. Repeat ERCP procedures were required in 93 (8.7%) patients and 45 (4.2%) had an
30
31 esophagogastroduodenoscopy (EGD) within 30 days of the index ERCP.
32
33
34
35
36
37
38

39 **Risk factors for AEs**

40
41 In order to determine if there were identifiable risk factors for AEs arising from ERCP in our
42
43 cohort, the relative frequency and distribution of patient and procedural characteristics were
44
45 compared between patients who had a procedural AE and those who did not (Table V). Patient
46
47 characteristics identified through multivariate analysis to be associated with AEs included: age
48
49 less than 45 years (OR 2.23 (95% CI 1.03 – 4.84) for age <45 years vs ≥65 years, $P=0.0498$);
50
51 and BMI ≥35 (OR 0.31 (95% CI 0.14 – 0.72) for BMI 25-34 vs ≥35, $P=0.0024$). Procedural
52
53 characteristics identified to be associated with increased risk of AEs included: patient's first
54
55
56
57
58
59
60

1
2
3 ERCP (OR 2.22 (95% CI 1.04 – 4.75), $P=0.0394$); pancreatic duct cannulation (OR 2.7 (95%CI
4 1.4 - 5.1), $P=0.0026$); outpatient procedure (OR 5.4 (95% CI 2.6 – 11.4), $P<0.0001$);
5
6
7
8 intraprocedure sphincterotomy bleeding (OR 10.0 (95% CI 3.8 – 26.1), $P<0.0001$); difficulty
9
10
11 grade (OR 8.9 (95% CI 1.9 – 43.1) for grade 4 vs 1, $P=0.0204$).

12 13 14 15 16 17 18 **DISCUSSION**

19
20 In the adult Olmsted County study population, which is considered representative of the US
21
22 population, ERCP utilization rates nearly doubled over the ten-year period from January 1, 1997
23
24 to December 31, 2006 from 58.0 to 104.8 cases per 100,000 persons/year¹⁵. This trend was
25
26 influenced by a substantial increase in the rate of therapeutic procedures and a slight decrease in
27
28 diagnostic procedures. Importantly, ERCP was performed predominantly for common ‘bread and
29
30 butter’ indications including cholangitis, biliary colic, and pancreatitis. This information
31
32 underscores the fact that ERCP is currently mainly a therapeutic modality, and should be
33
34 available at a community-based level. Training in ERCP should be focussed on gaining expertise
35
36 mainly for removal of common duct stones and relief of distal biliary obstruction. For a
37
38 community based gastroenterologist, the need for more complex procedures is rare, and these
39
40 procedures should be carried out at tertiary care centres.

41
42
43
44
45
46 ERCP utilization rates in Olmsted County in this study are in some ways divergent with
47
48 national data. For instance, Mazen Jamal et al queried the Nationwide Inpatient Sample (NIS)
49
50 data for ERCP utilization rates from 1996 to 2002¹⁶. They found that the rate of inpatient ERCPs
51
52 dropped from 74.95/100,000 persons in 1996 to 59.70/100,000 in 2002, driven mostly by a
53
54 decrease in diagnostic procedures, while there was a slight concomitant increase in therapeutic
55
56
57
58
59
60

1
2
3 procedures. However, because they were using NIS sample, data are not available on outpatient
4
5 utilization of ERCP. In contrast, outpatient procedures comprised 43.5% of procedures in our
6
7 study.
8
9

10 Over the study period, overall utilization of EUS and MRCP have also increased in
11
12 Olmsted County. ERCP is likely now utilized almost exclusively for therapeutic purposes
13
14 because of the diagnostic abilities of EUS and MRCP, and the improvements in contrast-
15
16 enhanced CT scans. Also, increased use of EUS and MRCP might actually result in more
17
18 therapeutic ERCP as seen in our study, which contradicts popular belief that utilization of ERCP
19
20 has decreased over time with increased use of other diagnostic modalities.
21
22
23

24
25 Unplanned admissions commonly occur after ERCP (22% within 30 days), but are most
26
27 often not related to procedural AEs, which occur in 5.3% of all patients undergoing ERCP.
28
29 Unplanned admissions within 30 days after a procedure are increasingly being counted as
30
31 negative indicators of healthcare quality¹⁷. However, our data suggest that in the case of ERCP,
32
33 this outcome measure may not be a valid indicator of the quality of the procedure itself and is
34
35 likely related to either underlying disease, a finding of the procedure itself that leads to elective
36
37 surgery, or possibly to other comorbidities. Identification and complete capture of 30-day
38
39 admissions is a strength of our study, in comparison to past studies, where capturing remote AEs
40
41 were incomplete⁶. Because this is a population-based study, and Mayo Clinic is the only
42
43 provider for ERCP in the population, all AEs were identified.
44
45
46
47

48 Severe procedural AEs, including pancreatitis (2.4%), bleeding (1.5%), infection (1.4%),
49
50 and mortality related to the procedure (0%), were uncommon. Most AEs were mild to moderate,
51
52 and at rates similar to previously published reports^{3 6}. In a systematic review of 21 surveys of
53
54 ERCP, AE rates in a population of 16,855 patients were 6.85%, with pancreatitis, infection and
55
56
57
58
59
60

1
2
3 bleeding occurring in 3.5%, 1.4% and 1.3% of cases³; mortality rate was 0.33%. Cotton et al.
4
5 reported on 11,497 procedures at multiple centers and found a 4.0% AE rate, with rates of 2.6%
6
7 for pancreatitis and 0.3% for bleeding. Mortality rate in this cohort was 0.06%⁶. Although 2.4%
8
9 of patients in our study died within 30 days of the ERCP, none of these deaths were ERCP-
10
11 related, and there were no intra- or peri-procedural deaths in our study. Because the AE rates in
12
13 our study are similar to the rates reported in the literature, it is likely that ERCP procedures
14
15 carried out at other tertiary care centres are also associated with low adverse event rates.
16
17
18
19

20 Numerous studies have enumerated various risk factors for AEs following ERCP^{6 8 10 18}
21
22 ¹⁹. Commonly accepted risk factors for any AE after ERCP include suspected sphincter of Oddi
23
24 dysfunction, cirrhosis, difficult cannulation, performance of precut sphincterotomy, percutaneous
25
26 biliary access, and lower ERCP case volumes, with young age, pancreatic duct contrast injection
27
28 and failed biliary drainage identified in some studies. In our study, younger patient age, higher
29
30 BMI, first ERCP, pancreatic duct cannulation, intra-procedural post sphincterotomy bleeding,
31
32 therapeutic procedures, and outpatient procedures were identified as risk factors for any AE
33
34 through a multivariate analysis.
35
36
37
38

39 Consistent with our findings, younger age has been previously shown to be a risk factor
40
41 for AEs, especially post-ERCP pancreatitis (PEP)^{5 8 10}. Pancreatic duct cannulation is known to
42
43 be a risk-factor for development of PEP⁶. Toward the end of this study period, data emerged
44
45 supporting the use of prophylactic pancreatic duct stents to decrease the incidence of PEP and
46
47 were published. In our study period, in only 59 (5.5%) procedures, we placed a pancreatic duct
48
49 stent. Hence, our study is not able to adequately define the rate of PEP with routine placement of
50
51 prophylactic pancreatic stents.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

One limitation of our study is that it is a retrospective review of data with its inherent biases. However, the data were manually abstracted by a single gastroenterologist from an electronic medical record, and significant adverse events and hospitalizations are not likely to have been missed. Another limitation is that even though the population studied is a county-based population, the skills of the endoscopists are at a higher level than endoscopists in smaller community hospitals. Therefore, the AE rate in this community setting could be lower than one would expect in community settings at large. While MRCP is widely available, wherever MRI is available, EUS availability is limited to those centres with trained endosonographers; it is possible that the latter may affect regional utilization of ERCP for diagnostic purposes. Another notable limitation is that Sphincter of Oddi dysfunction and complications of pancreatitis, diagnoses often referred to a tertiary center, were underrepresented in our study.

In conclusion, our study shows that utilization of ERCP at a population level continues to rise; specifically utilization of therapeutic procedures. The most common indications for ERCP remain relief of biliary colic or cholangitis, and this procedure may be carried out with moderate sedation. Adverse events of ERCP remain uncommon and deaths are infrequent. The study adds important epidemiologic data on trends in the utilization of ERCP, as well as population-based estimates of the risk of adverse events from ERCP that will be useful in clinical decision making and determination of resource allocation. The findings of the study may also impact ERCP training criteria.

ACKNOWLEDGEMENT

This publication was supported by NIH/NCRR CTSA Grant Number UL1 RR024150. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Funding

None

Competing Interests

None

Contributorship

Nayantara Coelho-Prabhu, MD - conception and design; analysis and interpretation of the data; drafting of the article; final approval of the article.

Nilay D. Shah, PhD - conception and design; analysis and interpretation of the data; critical revision of the article for important intellectual content.

Holly Van Houten - analysis and interpretation of the data.

Patrick S Kamath, MD - conception and design; critical revision of the article for important intellectual content.

Todd H Baron, MD, FASGE - conception and design; critical revision of the article for important intellectual content; final approval of the article.

Data sharing

Any additional data can be obtained from the corresponding author. This includes procedural details on all ERCPs including patient characteristics, indication, sedation, trainee involvement, therapies utilised during the ERCP, complications, billing codes.

REFERENCES

1. McCune WS, Shorb PE, Moscovitz H. Endoscopic cannulation of the ampulla of vater: a preliminary report. *Annals of surgery* 1968;167(5):752-6.
2. Adler DG, Baron TH, Davila RE, et al. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. *Gastrointestinal endoscopy* 2005;62(1):1-8.
3. Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. *The American journal of gastroenterology* 2007;102(8):1781-8.
4. Bodger K, Bowering K, Sarkar S, et al. All-cause mortality after first ERCP in England: clinically guided analysis of hospital episode statistics with linkage to registry of death. *Gastrointest Endosc* 2011;74(4):825-33.
5. Christensen M, Matzen P, Schulze S, et al. Complications of ERCP: a prospective study. *Gastrointestinal endoscopy* 2004;60(5):721-31.
6. Cotton PB, Garrow DA, Gallagher J, et al. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. *Gastrointestinal endoscopy* 2009;70(1):80-8.
7. Glomsaker T, Soreide K, Hoff G, et al. Contemporary use of endoscopic retrograde cholangiopancreatography (ERCP): a Norwegian prospective, multicenter study. *Scand J Gastroenterol* 2011;46(9):1144-51.
8. Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. *Gastrointestinal endoscopy* 1998;48(1):1-10.
9. Sieg A, Hachmoeller-Eisenbach U, Eisenbach T. Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. *Gastrointestinal endoscopy* 2001;53(6):620-7.
10. Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. *The American journal of gastroenterology* 2001;96(2):417-23.
11. Talley NJ, Jones M. Self-reported rectal bleeding in a United States community: prevalence, risk factors, and health care seeking. *The American journal of gastroenterology* 1998;93(11):2179-83.
12. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *Journal of chronic diseases* 1987;40(5):373-83.
13. Ragnath K, Thomas LA, Cheung WY, et al. Objective evaluation of ERCP procedures: a simple grading scale for evaluating technical difficulty. *Postgraduate medical journal* 2003;79(934):467-70.
14. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. *Gastrointestinal endoscopy* 1991;37(3):383-93.
15. St Sauver JL, Grossardt BR, Leibson CL, et al. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. *Mayo Clin Proc* 2012;87(2):151-60.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16. Mazen Jamal M, Yoon EJ, Saadi A, et al. Trends in the utilization of endoscopic retrograde cholangiopancreatography (ERCP) in the United States. *The American journal of gastroenterology* 2007;102(5):966-75.
 17. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. *The New England journal of medicine* 2009;360(14):1418-28.
 18. Freeman ML. Understanding risk factors and avoiding complications with endoscopic retrograde cholangiopancreatography. *Current gastroenterology reports* 2003;5(2):145-53.
 19. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. *The New England journal of medicine* 1996;335(13):909-18.

Figure Legends

Table IA. Morriston Hospital ERCP grading scale (Ragunath et al, Post Grad Med J, 2003)

Table IB. Consensus criteria for ERCP complications (Cotton et al, GIE, 1991)

Table II. Patient Characteristics

Table III. Procedural Characteristics

Table IV. Procedure Outcomes

Table V. Multivariate analysis of risk factors for post-ERCP complications

Figure I. Utilization characteristics of ERCP, EUS, and MRCP in Olmsted County over 10-year period.

Table IA: Morriston Hospital ERCP grading scale¹³

Procedure	Grade
Diagnostic ERCP	I
Biliary sphincterotomy, balloon sphincteroplasty, removal of extrahepatic stones ≤ 1 cm using basket and/or balloon	II
Precut sphincterotomy, large stones removal (>1 cm), intrahepatic stone removal, mechanical lithotripsy, stricture dilatation, cytology, stent insertion, and naso-biliary drain	III
Sphincter of Oddi manometry, diagnostic and therapeutic ERCP after Billroth II surgery, minor papilla sphincterotomy, endoscopic ampullectomy, and all pancreatic duct therapeutic procedures. Cholangioscopy, laser lithotripsy, electrohydraulic lithotripsy, combined procedures (PTC and ERCP), and other advanced bile duct therapeutic procedures	IV

ERCP - endoscopic retrograde cholangiopancreatography

PTC – percutaneous transhepatic cholangiography

Table IB: Consensus criteria for ERCP complications¹⁴

	Mild	Moderate	Severe
Bleeding	Clinical evidence of bleeding (ie not just endoscopic) Hemoglobin drop <3g No need for transfusion	Transfusion: 4 units or less No angiographic intervention or surgery	Transfusion: 5 units or more or intervention (angiographic or surgical)
Perforation	Possible, or only very slight leak of fluid or contrast dye Treatable by fluids and suction for 3 days or less	Any definite perforation treated medically for 4-10 days	Medical treatment for more than 10 days or intervention (percutaneous or surgical)
Pancreatitis	Clinical pancreatitis: amylase at least thrice the upper limit of normal at more than 24 hours after the procedure requiring admission or prolongation of planned admission to 2-3 days	Pancreatitis requiring hospitalization for 4-10 days	Pancreatitis requiring hospitalization for more than 10 days, or hemorrhagic pancreatitis, phlegmon, or intervention (percutaneous drainage or surgery)
Infection (cholangitis)	>38 degrees Celsius at 24-48 hours	Febrile or septic illness requiring >3 days of hospital treatment or endoscopic or percutaneous intervention	Septic shock or surgery

Table II: Patient Characteristics

Age at time of ERCP (years)	
mean (sd)	57.6 (19.8)
18-44 years	283 (26.4%)
45-64 years	357 (33.3%)
> 65+ years	432 (40.3%)
Gender	
Female, n (%)	522 (63.1)
Race	
Caucasian	688 (83.2%)
African American	15 (1.8%)
Other/unknown	124 (15.0%)
Charlson index at time of ERCP¹²	
mean (sd)	3.2 (3.2)
BMI at time of ERCP	
mean (sd)	28.5 (7.2)
< 25	341 (32.4%)
25-34	517 (49.1%)
35+	194 (18.4%)

ERCP – endoscopic retrograde cholangiopancreatography

BMI – body mass index

Table III: Procedural Characteristics

	(%)
Cholecystectomy within 30 days prior to ERCP	113 (10.5)
Altered anatomy	21 (2.0)
Anticoagulation	20 (1.9)
Prior ERCP	277 (25.8)
Biliary indications	975 (91.0)
Cholangitis	56 (5.2)
Cholecystitis	41 (3.8)
Bleeding	4 (0.4)
Choledocholithiasis	500 (46.6)
Malignant stricture	116 (10.8)
Hilar stricture	5 (0.5)
Benign stricture	46 (4.3)
Ca pancreas	21 (2)
Papillary stenosis	8 (0.7)
Ca ampulla	14 (1.3)
Anastomotic stricture	29 (2.7)
Post cholecystectomy	69 (6.4)
Suspected SOD	19 (1.8)
PSC	21 (2)
Bile leaks	23 (2.1)
Biliary colic	307 (28.6)
Biliary dilation	27 (2.5)
Stent removal	52 (4.9)
Elevated AST and ALT	76 (7.1)
Pancreatic indications	217 (20.2)
Acute pancreatitis	135 (12.6)
Recurrent acute pancreatitis	34 (3.2)
Chronic pancreatitis	17 (1.6)
Cyst	8 (0.7)
Duct leak	9 (0.8)
Duct stricture	7 (0.7)
Acute fluid collection	7 (0.7)
Chronic fluid collection	18 (1.7)
Necrosectomy	14 (1.3)
Inpatient	606 (56.5)

Therapeutic	889 (82.9)
Difficulty grade	
I	152 (14.2)
II	494 (46.1)
III	297 (27.7)
IV	129 (12.0)
Trainee present	667 (62.2)
Anesthesia	
Conscious sedation	1030 (96.1)
Fentanyl	51 (4.8)
Versed	1028 (95.8)
Benadryl	6 (0.6)
Demerol	979 (91.2)
Phenergan	90 (8.4)
Droperidol	25 (2.3)
General (or propofol)	42 (3.9)
Peri-ampullary diverticulum	117 (10.9)
Biliary sphincterotomy	620 (57.8)
Precut biliary sphincterotomy	125 (11.7)
Biliary stent placed	185 (17.3)
Pancreatic sphincterotomy	13 (1.2)
Pancreatic duct stent placed	59 (5.5)
Ampullectomy	7 (0.7)
Transgastric/transduodenal drainage	16 (1.5)
Sphincterotomy bleeding noted during procedure	45 (4.2)

ERCP – endoscopic retrograde cholangiopancreatography

AST – aspartate aminotransferase

ALT – alanine aminotransferase

Table IV: Procedure Outcomes


	(%)
Success	041 (97.1)
Death	
During procedure	0 (0.0)
Within 30 days	26 (2.4)
Need for repeat procedure within 30 days	
ERCP	93 (8.7)
EGD	45 1 (4.2)
Number of readmissions within 30 days	273
Definitely related to procedure	62 (22.7)
Possibly related to procedure	6 (2.2)
Definitely not related to procedure	205 (75.1)
Surgery within 30 days	
Elective cholecystectomy	52 (4.9)
Elective Whipple	16 (5.9)
Other elective	11 (4.0)
Emergent cholecystectomy	6 (2.2)
ERCP complications requiring readmit	53 (4.9)
Pancreatitis	26 (2.4)
Mild	18
Moderate	8
Severe	0
Infection/cholangitis	16 (1.5)
Mild	6
Moderate	7
Severe	3
Bleeding	15 (1.4)
Mild	6
Moderate	8
Severe	1
Perforation	4 (0.37)
Mild	0
Moderate	0

Severe	4
--------	---

Table V. Multivariate analysis of risk factors for post-ERCP complications

Risk factor	Odds ratio (95% CI)	P-value
Age <45 vs ≥65	2.23 (1.03 – 4.84)	0.0498 *
Age 45-64 vs ≥65	1.3 (0.62 – 2.72)	0.6697
Female gender	1.2 (0.61 – 2.21)	0.6412
BMI <25 vs ≥35	0.84 (0.40 – 1.74)	0.1972
BMI 25-34 vs ≥35	0.31 (0.14 – 0.72)	0.0024 *
No previous ERCP	2.22 (1.04 – 4.75)	0.0394 *
Outpatient ERCP	5.4 (2.6 – 11.4)	<0.0001 *
Pancreatic duct cannulation	2.7 (1.4 – 5.1)	0.0026 *
Absence of trainee	1.36 (0.72 – 2.59)	0.3487
Intraprocedure sphincterotomy bleeding	10.0 (3.8 – 26.1)	<0.0001 *
Difficulty grade 1 vs 4	0.11 (0.02 – 0.54)	0.0204 *
Difficulty grade 2 vs 4	0.45 (0.18 – 1.14)	0.9199
Difficulty grade 3 vs 4	0.94 (0.42 – 2.13)	0.0129 *

Figure 1.



119x90mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE STATEMENT checklist of items that should be included in reports of Observational Studies

SECTION/TOPIC	Item No.	Checklist Item	Reported on page No.
TITLE AND ABSTRACT	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	<u>2</u>
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	<u>2, 3</u>
INTRODUCTION			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	<u>4</u>
Objectives	3	State specific objectives, including any pre-specified hypotheses	<u>4, 5</u>
METHODS			
Study design	4	Present key elements of study design early in the paper	<u>5</u>
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	<u>5,6</u>
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	<u>5,6</u>
		(b) <i>Cohort study</i> —For match studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	<u>6,7</u>
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	<u>6,7</u>
Bias	9	Describe any efforts to address potential sources of bias	<u>8</u>
Study size	10	Explain how the study size was arrived at	<u>8</u>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	<u>8</u>
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	<u>7,8</u>
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
RESULTS			
Participants	13*	(a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed	<u>8</u>
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders	<u>8,9</u>
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarize follow-up time (e.g., average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	<u>10</u>
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make	<u>10</u>

Formatted: Font: Italic
Formatted: Font: Italic

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

		clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	(d) Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	
DISCUSSION			
Key results	18	Summarize key results with reference to study objectives	12,13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalizability	21	Discuss the generalizability (external validity) of the study results	15
OTHER INFORMATION			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

Endoscopic Retrograde Cholangiopancreatography – Utilization and outcomes in a 10-year population based cohort

Nayantara Coelho-Prabhu, MD¹; Nilay D. Shah, PhD²; Holly Van Houten²;

Patrick S Kamath, MD¹; Todd H Baron, MD, FASGE¹

¹ Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA

² Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN, USA

Financial support and disclosure – none.

Corresponding author – Nayantara Coelho-Prabhu, MD

200 First Street SW

Rochester, MN 55905, USA

Coelhoprabhu.nayantara@mayo.edu

Tel – 001-507-284-2407

Fax – 001-507-284-0538

Extra data is available by contacting the corresponding author.

Word count – Text – 3197

Tables – 5

Figures – 1

Keywords: ERCP, utilization, complications, hospitalization

SUMMARY

Article Focus:

- Due to increasing use of quality metrics, accurate measures of utilization and procedural adverse event risks are necessary to establish benchmarks for quality, and are best determined from community-based studies.
- There are no reports of community-based utilization of ERCP in the US.
- The aims of this population-based study were to determine the utilization of ERCP including changes over time, the incidence of inpatient admissions for adverse events within 30 days of ERCP, and risk factors for procedural related adverse events.

Key Messages:

- Population utilization of ERCP in Olmsted County MN rose over the ten year period from 1997 to 2006, driven specifically by increases in therapeutic procedures. The most common indications for ERCP were therapy of choledocholithiasis and to determine etiology of acute pancreatitis.
- Admissions within 30 days after ERCP are common, but are usually unrelated. Complications of ERCP remain **infrequent** at 5.3% and no deaths were directly related.
- Risk factors associated with adverse events from ERCP include younger age, BMI ≥ 35 , pancreatic duct cannulation, outpatient procedures, intraprocedure sphincterotomy bleeding, difficulty grade, and patient's first ERCP.

Strengths and Limitations:

Strengths:

- Population-based epidemiologic research can be conducted in Olmsted County because medical care is virtually self-contained within the community.
- The unique advantage of our data is that Mayo Clinic is the only center performing ERCP in the entire county and, therefore, population based utilization and adverse events of ERCP with full details of procedures and subsequent hospitalizations can be assessed.

Limitations:

- The study is a retrospective review with inherent potential biases.
- The skills of the endoscopists are likely at a higher level than endoscopists in smaller community hospitals. Therefore, the adverse event rate in this community setting could be lower than one would expect in other community settings.

ABSTRACT

Objective: To determine utilization of ERCP; incidence of inpatient admissions for complications occurring within 30 days of ERCP; and risk factors for procedural related complications, in a population based study.

Design: Retrospective cohort study

Setting: Olmsted County, MN

Participants: All adult residents of Olmsted County, MN, who underwent ERCP from 1997 to 2006.

Interventions: Diagnostic and therapeutic ERCPs were assessed.

Primary and Secondary outcome measures: Patient and procedural characteristics and complications within 30 days; and rates of ERCP utilization and unplanned admissions and risk factors for admissions.

Results: In ten years, 1072 ERCPs were performed on 827 individual patients. Average utilization of ERCP was 83.1 ERCPs/100,000 persons/year, with an increase from 58.0 to 104.8 ERCPs/100,000 persons/year over time, driven by increases in therapeutic procedures. Within 30 days after 236 procedures, 62 admissions were definitely related to the index ERCP. The complication rate was 5.3%, including pancreatitis(26, 2.4%), infection/cholangitis(16, 1.5%),

1
2
3 bleeding(15, 1.4%), and perforation(4, 0.37%). 30-day mortality was 2.4%; none of which were
4
5 directly related to the ERCP or complications thereof. Risk factors identified through
6
7
8 multivariate analysis to be associated with adverse events included: age <45 years(p=0.0498);
9
10 BMI \geq 35(p=0.0024); pancreatic duct cannulation(p=0.0026); outpatient procedure(p<0.0001);
11
12 intraprocedure sphincterotomy bleeding(P <0.0001); difficulty grade(P =0.115); and patient's first
13
14 ERCP(P =0.0394).
15
16
17
18
19

20 **Limitations:** Retrospective study.
21
22
23

24 **Conclusions:** Population utilization of ERCP rose during the study period, specifically in
25
26 therapeutic procedures. Admissions within 30 days of ERCP are common, but often unrelated.
27
28 Complications of ERCP remain infrequent and deaths quite unusual.
29
30
31
32
33
34
35
36
37
38

39 **Abbreviations:**

40 AE – adverse event

41 EGD – esophagogastroduodenoscopy

42 ERCP - endoscopic retrograde cholangiopancreatography

43 EUS – endoscopic ultrasound

44 MRCP - magnetic resonance cholangiopancreatography
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BACKGROUND

Since its first description in 1968, endoscopic retrograde cholangiopancreatography (ERCP) has become an established modality for the diagnosis and treatment of pancreaticobiliary disorders^{1 2}. Over the years, ERCP has evolved from a purely diagnostic, to a mainly therapeutic procedure. Around 500,000 ERCPs are performed annually in the United States (US) with adverse event (AE) rates between 4% and 10%,³ and mortality between 0.05% and 1%⁴⁻⁷. The most common AEs following ERCP include pancreatitis, hemorrhage, and infection, which occurred in 4% to 7% of procedures^{3 6 8}. There is an increased risk of AEs after therapeutic procedures and in patients with suspected Sphincter of Oddi dysfunction⁶. Since ERCP is the endoscopic procedure with the highest cost and AE rates, diagnostic ERCP is now avoided in favor of other diagnostic modalities such as less-invasive endoscopic ultrasound (EUS) and non-invasive magnetic resonance cholangiopancreatography (MRCP)^{2 3 9}. In an era of increasing utilization of quality metrics, accurate measures of utilization rates and procedural adverse event risks are necessary to establish meaningful benchmarks for quality, and are best determined from community-based studies.

There are no reports of community-based utilization of ERCP in the US, but there are several from Europe^{8 10}. Published reports of ERCP related AEs have all been single-centered or multi-centered studies from tertiary care centers and affected by referral bias, leading to high estimates of risk that may not apply to the general population. All adverse events of procedures done at tertiary care centers may not be captured since the patients may seek care for AEs closer to their homes and thus, lost to follow-up.

The aims of this population-based study were to determine (1) the utilization of ERCP, including changes over time; (2) the incidence of inpatient admissions for AEs within 30 days of

1
2
3 ERCP; and (3) risk factors for procedural related AEs among residents of Olmsted County, MN
4
5 over a ten-year period from 1997-2006. The findings of this study are unique, as they represent
6
7 population based estimates of utilization and risks associated with ERCP and may serve as more
8
9 accurate and clinically meaningful data for clinical decision making and development of quality
10
11 benchmarks.
12
13

14 15 16 17 **METHODS**

18
19 Study Design: A retrospective cohort study was conducted with approval of the Institutional
20
21 Review Board of Mayo Clinic in compliance with federal regulations of the U.S. Department of
22
23 Health and Human Services for protection of human subjects and the Health Information
24
25 Protection and Portability Act. All patients provided consent for medical record review. Billing
26
27 records from Mayo Clinic and associated hospitals were queried for Olmsted County residents
28
29 who had undergone an ERCP during a ten-year period from January 1, 1997 to December 31,
30
31 2006. ERCPs were identified using CPT codes for ERCP, including 43260, 43261, 43262,
32
33 43263, 43264, 43265, 43267, 43268, 43269, 43271, 43272, and 47999. Utilization characteristics
34
35 for EUS were determined in the same population using codes 43232, 43238, and 43242 and for
36
37 MRCP using codes 74181, 74182, and 74183. Subjects also had to be age ≥ 18 years, live in
38
39 Olmsted County, and have valid authorization to review medical records for research purposes in
40
41 accordance with Minnesota State statutes.
42
43
44
45
46
47

48
49 Population-based epidemiologic research can be conducted in Olmsted County because
50
51 medical care is virtually self-contained within the community. Olmsted County comprises over
52
53 100,000 persons, of whom 85% are Caucasian and 50% are women; socio-demographically, the
54
55 community is similar to the US population. Over half of the county's population is seen at one of
56
57
58
59
60

1
2
3 the Mayo Clinic facilities; 95% of local residents will have had at least one medical contact with
4 a local care provider (*e.g.*, for dental X-rays, sports physical examinations, pre-employment
5 examinations, minor illness, and routine medical care) during any 4-year period¹¹. Mayo Clinic
6 has a common medical record system with its two affiliated hospitals (Saint Mary's and
7 Rochester Methodist) for 90 years. Mayo Clinic's single record system contains both inpatient
8 and outpatient data. Diagnoses and surgical procedures recorded in these records are indexed. It
9 includes diagnoses made for outpatients seen in office or clinic consultations, emergency room
10 visits, and diagnoses recorded for hospital inpatients, autopsy examinations, or on death
11 certificates. The unique advantage of our data is that Mayo Clinic is the only center performing
12 ERCP in the entire county and, therefore, population based utilization and AEs of ERCP with
13 full details of the hospitalization can be assessed.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 Medical records were reviewed retrospectively by the primary author. Patient and
30 procedural characteristics, as well as AEs within 30 days were recorded. As many as 170
31 variables were collected for each procedure and recorded into a database.
32
33
34
35

36 Primary outcomes measured were (1) utilization rates of unique ERCP procedures in the
37 adult population (age 18 years and older) of Olmsted County from 1997-2006, and (2) the rate of
38 unplanned admissions within 30 days following ERCP for ERCP-related AEs. Secondary
39 outcomes included patient and procedural characteristics, predictive of having an unplanned
40 admission within 30 days after ERCP for an ERCP-related AE.
41
42
43
44
45
46
47

48 Utilization metrics included the patients' age, sex, race, Charlson score at the time of
49 ERCP¹², body mass index (BMI), cholecystectomy within 30 days prior to ERCP, altered
50 anatomy (including gastrojejunostomy, Whipple anatomy, hepatico- and choledocho-
51 jejunostomy), presence of cirrhosis, and previous history of ERCP. Indications for ERCP were
52
53
54
55
56
57
58
59
60

1
2
3 then examined as biliary versus pancreatic, diagnostic versus therapeutic, and graded for
4
5 complexity using the previously published Morriston Hospital ERCP grading scale (Table IA)¹³.
6
7
8 Diagnostic procedures had a CPT code of 43260 where no intervention was performed, other
9
10 than a cholangiogram or pancreatogram; all other procedures were therapeutic. Multiple intra-
11
12 procedural details, including presence of a trainee, type and amount of sedation used, and biliary
13
14 and pancreatic ductal interventions were noted. Success of the procedure was recorded as the
15
16 ability to cannulate the intended duct and achieve the intended therapy.
17
18

19
20 AEs recorded included unplanned admissions; sedation-related events, including
21
22 pulmonary and cardiovascular events; infection; pancreatitis; bleeding; perforation; need for
23
24 repeat endoscopic procedure; or mortality within 30 days. These outcomes were determined as
25
26 being related to the index ERCP by author review. AEs were deemed to be definitely related,
27
28 probably related, possibly related, or definitely unrelated to the index ERCP. Possibly related
29
30 AEs included patients admitted with abdominal pain, but without evidence of definite
31
32 pancreatitis by laboratory studies or documented cholangitis. Probably related AEs included
33
34 biliary or pancreatic stent dysfunction leading to repeat the procedure within 30 days of the index
35
36 procedure, but without any of the defined AEs of pancreatitis, infection, perforation, and
37
38 gastrointestinal bleeding. The latter AEs were categorized as mild, moderate, and severe,
39
40 according to established consensus criteria (Table IB)^{6 14} Patients undergoing elective surgery
41
42 including cholecystectomy within 30 days of ERCP were also identified.
43
44
45
46
47
48
49

50 51 **Statistical Analysis**

52
53 Univariate analyses were performed to obtain descriptive statistics for patient and procedural
54
55 characteristics. Annual incidence was determined by dividing the number of ERCPs performed
56
57
58
59
60

1
2
3 on the study subjects during a calendar year by the adult population of Olmsted County during
4 that period, according to County records and normalized to 100,000 persons. To test for
5 associations between patient and procedural characteristics and ERCP related AEs, values of
6 these characteristics were compared between subjects who experienced ERCP-related AEs and
7 subjects who did not by two sample t-tests for continuous variables, and chi square test for
8 discrete variables. Multivariable logistic regression analyses were used to determine patient and
9 procedural characteristics predictive of ERCP-related AEs. *P*-values less than 0.05 were
10 considered statistically significant. All analyses for this study were done using SAS statistical
11 software (SAS version 9.1 for Windows; SAS Institute Inc., Cary, North Carolina).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 RESULTS

28 Demographic characteristics

29
30 In the 10-year period from January, 1, 1997 to December, 31, 2006, 1072 ERCPs were
31 performed on 827 individual adult residents of Olmsted County. The total number of ERCPs
32 done during this time period was 13056 including the non-residents of Olmsted County. Patient
33 demographic characteristics can be seen in Table II. Prior to the index cholecystectomy, 232
34 (28%) patients had a previous cholecystectomy; 21 (2%) patients had altered anatomy, and 20
35 (1.9%) were taking clopidogrel or warfarin at the time of the ERCP. There were 153 patients
36 who had more than one ERCP during the 10-year period, and the mean number of ERCPs in
37 these patients was 1.3.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 Utilization characteristics

56
57
58
59
60

1
2
3 Average utilization of ERCP was 83.1 ERCPs per 100,000 persons/year, with an increasing trend
4
5 in utilization from 58.0 to 104.8 ERCPs per 100,000 persons/year over the 10-year period.
6
7
8 Therapeutic ERCPs increased over the same timeframe from 42.9 to 93.9 ERCPs per 100,000
9
10 persons/year (average 68.7). However, diagnostic ERCPs decreased slightly from 15.1 to 10.9
11
12 and averaged 14.4 ERCPs per 100,000 persons/year. EUS and MRCP utilization in the same
13
14 population also steadily increased over this time period (Figure I).
15
16
17
18
19

20 **Procedural characteristics**

21
22 Procedural characteristics can be seen in Table III. Of the 1072 ERCPs performed over the 10-
23
24 year period, 606(56.5%) were performed **on inpatients**, while 889 (82.9%) were therapeutic. The
25
26 proportion of therapeutic procedures from 2002-2006 was higher than from 1997-2001 (86.6%
27
28 vs 77.5%, $P=0.0001$). The difficulty grades, as defined by Morrison Hospital ERCP grading
29
30 scale, were mostly Grade II(494, 46.1%) and Grade III(297, 27.7%) procedures overall;
31
32 however, there was a two-fold increase in Grade IV procedures in the second five-year period,
33
34 compared to the first (15.3% vs 7.2%, $P<0.0001$). ERCP was performed primarily for a biliary
35
36 indication in 853 (79.6%) and a pancreatic indication in 95 (8.9%) with 122 (11.4%) for both a
37
38 biliary and pancreatic indication. The commonest biliary indications included choledocholithiasis
39
40 (500, 46.6%), biliary colic in the absence of documented choledocholithiasis (307, 28.6%), and
41
42 relief of malignant biliary obstruction (116, 10.8%). The commonest pancreatic indications for
43
44 ERCP were to determine etiology of acute pancreatitis (135, 12.6%), or recurrent acute
45
46 pancreatitis (34, 3.2%), and chronic pancreatic fluid collection (18, 1.7%). Suspected sphincter
47
48 of Oddi dysfunction was the indication in only (19, 1.7%) of ERCPs. A trainee was involved in
49
50 667 (62.2%) cases.
51
52
53
54
55
56
57
58
59
60

1
2
3 Biliary sphincterotomy was performed in 620 (57.8%) procedures; the pancreatic duct
4 was injected in 404 (37.7%) cases and was cannulated in 255 (23.8%) procedures. In some cases,
5
6 the intent was to cannulate the bile duct, but pancreatic duct injection occurred during the
7
8 process. Biliary stents were placed in 185 (17.3%) cases; prophylactic pancreatic stents were
9
10 placed in 59 (5.5%) patients. Placement of pancreatic stents increased in the second 5-year
11
12 period, compared to the first (8.1% vs 1.6%, $P<0.0001$). Ampullectomy was performed in 7
13
14 (0.7%) cases and 16 (1.5%) cases were transgastric or transduodenal débridements of pancreatic
15
16 necrosis (15 of which occurred in the second 5-year period, $P=0.0053$). Only 31 (2.9%) of
17
18 ERCPs were deemed as failures as the goal of the procedure was not achieved, resulting in a
19
20 97.1% success rate. None of the patients received any prophylaxis to prevent post-ERCP
21
22 pancreatitis.
23
24
25
26
27
28
29
30
31

32 Sedation

33
34 Only 42(3.9%) of procedures were done with anesthesia support. Of the remaining ERCPs done
35
36 under moderate sedation, the mean dose of fentanyl was 159 ± 86 mcg (in 51 ERCPs),
37
38 midazolam 6.1 ± 2.6 mg (1028 ERCPs), meperidine 97 ± 46 mg (979 ERCPs), and promethazine
39
40 21 ± 8 mg (90 ERCPs).
41
42
43
44
45

46 Outcomes

47
48 Following 1072 ERCPs in Olmsted County, over ten years, there were 273 admissions to the
49
50 hospital within 30 days after 236 procedures (22% of all procedures). Table IV lists the outcomes
51
52 in the study cohort. Of the 273 admissions, only 62 (22.7%) were definitely related to the index
53
54 ERCP procedure, with another 2 (0.7%) probably related, and 4 (1.4%) possibly related to the
55
56
57
58
59
60

1
2
3 procedure. Of the remaining 205 admissions unrelated to procedural AEs of the index ERCP, 79
4
5 were planned for elective surgeries, including cholecystectomy. Intraprocedural AEs were
6
7 **infrequent**, with 20 (1.9%) necessitating a change in intra-procedural anesthesia; no deaths
8
9 occurred during the procedure. There were 47 sphincterotomy-induced intra-procedural bleeding
10
11 episodes treated with various modalities, including epinephrine injection, cautery and
12
13 tamponade.
14

15
16
17 The AE rate was 5.3% including pancreatitis (26, 2.4%), infection/cholangitis (16, 1.5%),
18
19 bleeding (15, 1.4%), and perforation (4, 0.37%). 53 cases were determined to be mild to
20
21 moderate; however, 3 infections, all 4 perforations, and 1 bleed were considered severe. The 30-
22
23 day mortality rate was 2.4%. **69% of deaths were due to underlying malignancy, 12% were due**
24
25 **to infections unrelated to the ERCP, and 19% were due to other causes including stroke,**
26
27 **respiratory failure, and dementia.** None of the deaths were directly related to the ERCP or AEs
28
29 thereof. Repeat ERCP procedures were required in 93 (8.7%) patients and 45 (4.2%) had an
30
31 esophagogastroduodenoscopy (EGD) within 30 days of the index ERCP.
32
33
34
35
36
37
38

39 **Risk factors for AEs**

40
41 In order to determine if there were identifiable risk factors for AEs arising from ERCP in our
42
43 cohort, the relative frequency and distribution of patient and procedural characteristics were
44
45 compared between patients who had a procedural AE and those who did not (Table V). Patient
46
47 characteristics identified through multivariate analysis to be associated with AEs included: age
48
49 less than 45 years (OR 2.23 (95% CI 1.03 – 4.84) for age <45 years vs ≥65 years, $P=0.0498$);
50
51 and BMI ≥35 (OR 0.31 (95% CI 0.14 – 0.72) for BMI 25-34 vs ≥35, $P=0.0024$). Procedural
52
53 characteristics identified to be associated with increased risk of AEs included: patient's first
54
55
56
57
58
59
60

1
2
3 ERCP (OR 2.22 (95% CI 1.04 – 4.75), $P=0.0394$); pancreatic duct cannulation (OR 2.7 (95%CI
4
5 1.4 - 5.1), $P=0.0026$); outpatient procedure (OR 5.4 (95% CI 2.6 – 11.4), $P<0.0001$);
6
7
8 intraprocedure sphincterotomy bleeding (OR 10.0 (95% CI 3.8 – 26.1), $P<0.0001$); difficulty
9
10 grade (OR 8.9 (95% CI 1.9 – 43.1) for grade 4 vs 1, $P=0.0204$).

17 DISCUSSION

18
19
20 In the adult Olmsted County study population, which is considered representative of the US
21
22 population, ERCP utilization rates nearly doubled over the ten-year period from January 1, 1997
23
24 to December 31, 2006 from 58.0 to 104.8 cases per 100,000 persons/year¹⁵. This trend was
25
26 influenced by a substantial increase in the rate of therapeutic procedures and a slight decrease in
27
28 diagnostic procedures. Importantly, ERCP was performed predominantly for common ‘bread and
29
30 butter’ indications including cholangitis, biliary colic, and pancreatitis. This information
31
32 underscores the fact that ERCP is currently mainly a therapeutic modality, and should be
33
34 available at a community-based level. Training in ERCP should be focussed on gaining expertise
35
36 mainly for removal of common duct stones and relief of distal biliary obstruction. For a
37
38 community based gastroenterologist, the need for more complex procedures is rare, and these
39
40 procedures should be carried out at tertiary care centres.

41
42
43
44
45
46 ERCP utilization rates in Olmsted County in this study are in some ways divergent with
47
48 national data. For instance, Mazen Jamal et al queried the Nationwide Inpatient Sample (NIS)
49
50 data for ERCP utilization rates from 1996 to 2002¹⁶. They found that the rate of inpatient ERCPs
51
52 dropped from 74.95/100,000 persons in 1996 to 59.70/100,000 in 2002, driven mostly by a
53
54 decrease in diagnostic procedures, while there was a slight concomitant increase in therapeutic
55
56
57
58
59
60

1
2
3 procedures. However, because they were using NIS sample, data are not available on outpatient
4
5 utilization of ERCP. In contrast, outpatient procedures comprised 43.5% of procedures in our
6
7 study.
8
9

10 Over the study period, overall utilization of EUS and MRCP have also increased in
11
12 Olmsted County. ERCP is likely now utilized almost exclusively for therapeutic purposes
13
14 because of the diagnostic abilities of EUS and MRCP, and the improvements in contrast-
15
16 enhanced CT scans. Also, increased use of EUS and MRCP might actually result in more
17
18 therapeutic ERCP as seen in our study, which contradicts popular belief that utilization of ERCP
19
20 has decreased over time with increased use of other diagnostic modalities.
21
22
23

24
25 Unplanned admissions commonly occur after ERCP (22% within 30 days), but are most
26
27 often not related to procedural AEs, which occur in 5.3% of all patients undergoing ERCP.
28
29 Unplanned admissions within 30 days after a procedure are increasingly being counted as
30
31 negative indicators of healthcare quality¹⁷. However, our data suggest that in the case of ERCP,
32
33 this outcome measure may not be a valid indicator of the quality of the procedure itself and is
34
35 likely related to either underlying disease, a finding of the procedure itself that leads to elective
36
37 surgery, or possibly to other comorbidities. Identification and complete capture of 30-day
38
39 admissions is a strength of our study, in comparison to past studies, where capturing remote AEs
40
41 were incomplete⁶. Because this is a population-based study, and Mayo Clinic is the only
42
43 provider for ERCP in the population, all AEs were identified.
44
45
46
47

48 Severe procedural AEs, including pancreatitis (2.4%), bleeding (1.5%), infection (1.4%),
49
50 and mortality related to the procedure (0%), were uncommon. Most AEs were mild to moderate,
51
52 and at rates similar to previously published reports^{3 6}. In a systematic review of 21 surveys of
53
54 ERCP, AE rates in a population of 16,855 patients were 6.85%, with pancreatitis, infection and
55
56
57
58
59
60

1
2
3 bleeding occurring in 3.5%, 1.4% and 1.3% of cases³; mortality rate was 0.33%. Cotton et al.
4
5 reported on 11,497 procedures at multiple centers and found a 4.0% AE rate, with rates of 2.6%
6
7 for pancreatitis and 0.3% for bleeding. Mortality rate in this cohort was 0.06%⁶. Although 2.4%
8
9 of patients in our study died within 30 days of the ERCP, none of these deaths were ERCP-
10
11 related, and there were no intra- or peri-procedural deaths in our study. Because the AE rates in
12
13 our study are similar to the rates reported in the literature, it is likely that ERCP procedures
14
15 carried out at other tertiary care centres are also associated with low adverse event rates.
16
17
18
19

20 Numerous studies have enumerated various risk factors for AEs following ERCP^{6 8 10 18}
21
22 ¹⁹. Commonly accepted risk factors for any AE after ERCP include suspected sphincter of Oddi
23
24 dysfunction, cirrhosis, difficult cannulation, performance of precut sphincterotomy, percutaneous
25
26 biliary access, and lower ERCP case volumes, with young age, pancreatic duct contrast injection
27
28 and failed biliary drainage identified in some studies. In our study, younger patient age, higher
29
30 BMI, first ERCP, pancreatic duct cannulation, intra-procedural post sphincterotomy bleeding,
31
32 therapeutic procedures, and outpatient procedures were identified as risk factors for any AE
33
34 through a multivariate analysis.
35
36
37
38

39 Consistent with our findings, younger age has been previously shown to be a risk factor
40
41 for AEs, especially post-ERCP pancreatitis (PEP)^{5 8 10}. Pancreatic duct cannulation is known to
42
43 be a risk-factor for development of PEP⁶. Toward the end of this study period, data emerged
44
45 supporting the use of prophylactic pancreatic duct stents to decrease the incidence of PEP and
46
47 were published. In our study period, in only 59 (5.5%) procedures, we placed a pancreatic duct
48
49 stent. Hence, our study is not able to adequately define the rate of PEP with routine placement of
50
51 prophylactic pancreatic stents.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

One limitation of our study is that it is a retrospective review of data with its inherent biases. However, the data were manually abstracted by a single gastroenterologist from an electronic medical record, and significant adverse events and hospitalizations are not likely to have been missed. Another limitation is that even though the population studied is a county-based population, the skills of the endoscopists are at a higher level than endoscopists in smaller community hospitals. Therefore, the AE rate in this community setting could be lower than one would expect in community settings at large. While MRCP is widely available, wherever MRI is available, EUS availability is limited to those centres with trained endosonographers, it is possible that the latter may affect regional utilization of ERCP for diagnostic purposes. Another notable limitation is that Sphincter of Oddi dysfunction and complications of pancreatitis, diagnoses often referred to a tertiary center, were underrepresented in our study.

In conclusion, our study shows that utilization of ERCP at a population level continues to rise; specifically utilization of therapeutic procedures. The most common indications for ERCP remain relief of biliary colic or cholangitis, and this procedure may be carried out with moderate sedation. Adverse events of ERCP remain uncommon and deaths are infrequent. The study adds important epidemiologic data on trends in the utilization of ERCP, as well as population-based estimates of the risk of adverse events from ERCP that will be useful in clinical decision making and determination of resource allocation. The findings of the study may also impact ERCP training criteria.

ACKNOWLEDGEMENT

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

This publication was supported by NIH/NCRR CTSA Grant Number UL1 RR024150. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2013-002689 on 29 May 2013. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

REFERENCES

1. McCune WS, Shorb PE, Moscovitz H. Endoscopic cannulation of the ampulla of Vater: a preliminary report. *Annals of surgery* 1968;167(5):752-6.
2. Adler DG, Baron TH, Davila RE, Egan J, Hirota WK, Leighton JA, et al. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. *Gastrointestinal endoscopy* 2005;62(1):1-8.
3. Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. *The American journal of gastroenterology* 2007;102(8):1781-8.
4. Bodger K, Bowering K, Sarkar S, Thompson E, Pearson MG. All-cause mortality after first ERCP in England: clinically guided analysis of hospital episode statistics with linkage to registry of death. *Gastrointest Endosc* 2011;74(4):825-33.
5. Christensen M, Matzen P, Schulze S, Rosenberg J. Complications of ERCP: a prospective study. *Gastrointestinal endoscopy* 2004;60(5):721-31.
6. Cotton PB, Garrow DA, Gallagher J, Romagnuolo J. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. *Gastrointestinal endoscopy* 2009;70(1):80-8.
7. Glomsaker T, Soreide K, Hoff G, Aabakken L, Soreide JA. Contemporary use of endoscopic retrograde cholangiopancreatography (ERCP): a Norwegian prospective, multicenter study. *Scand J Gastroenterol* 2011;46(9):1144-51.
8. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. *Gastrointestinal endoscopy* 1998;48(1):1-10.
9. Sieg A, Hachmoeller-Eisenbach U, Eisenbach T. Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. *Gastrointestinal endoscopy* 2001;53(6):620-7.
10. Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. *The American journal of gastroenterology* 2001;96(2):417-23.
11. Talley NJ, Jones M. Self-reported rectal bleeding in a United States community: prevalence, risk factors, and health care seeking. *The American journal of gastroenterology* 1998;93(11):2179-83.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *Journal of chronic diseases* 1987;40(5):373-83.
13. Ragnath K, Thomas LA, Cheung WY, Duane PD, Richards DG. Objective evaluation of ERCP procedures: a simple grading scale for evaluating technical difficulty. *Postgraduate medical journal* 2003;79(934):467-70.
14. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. *Gastrointestinal endoscopy* 1991;37(3):383-93.
15. St Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ, 3rd, Rocca WA. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. *Mayo Clin Proc* 2012;87(2):151-60.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
16. Mazen Jamal M, Yoon EJ, Saadi A, Sy TY, Hashemzadeh M. Trends in the utilization of endoscopic retrograde cholangiopancreatography (ERCP) in the United States. *The American journal of gastroenterology* 2007;102(5):966-75.
 17. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. *The New England journal of medicine* 2009;360(14):1418-28.
 18. Freeman ML. Understanding risk factors and avoiding complications with endoscopic retrograde cholangiopancreatography. *Current gastroenterology reports* 2003;5(2):145-53.
 19. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. *The New England journal of medicine* 1996;335(13):909-18.

Figure Legends

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table IA. Morriston Hospital ERCP grading scale (Ragunath et al, Post Grad Med J, 2003)

Table IB. Consensus criteria for ERCP complications (Cotton et al, GIE, 1991)

Table II. Patient Characteristics

Table III. Procedural Characteristics

Table IV. Procedure Outcomes

Table V. Multivariate analysis of risk factors for post-ERCP complications

Figure I. Utilization characteristics of ERCP, EUS, and MRCP in Olmsted County over 10-year period.

Table IA: Morriston Hospital ERCP grading scale¹³

Procedure	Grade
Diagnostic ERCP	I
Biliary sphincterotomy, balloon sphincteroplasty, removal of extrahepatic stones ≤ 1 cm using basket and/or balloon	II
Precut sphincterotomy, large stones removal (>1 cm), intrahepatic stone removal, mechanical lithotripsy, stricture dilatation, cytology, stent insertion, and naso-biliary drain	III
Sphincter of Oddi manometry, diagnostic and therapeutic ERCP after Billroth II surgery, minor papilla sphincterotomy, endoscopic ampullectomy, and all pancreatic duct therapeutic procedures. Cholangioscopy, laser lithotripsy, electrohydraulic lithotripsy, combined procedures (PTC and ERCP), and other advanced bile duct therapeutic procedures	IV

ERCP - endoscopic retrograde cholangiopancreatography

PTC – percutaneous transhepatic cholangiography

Table IB: Consensus criteria for ERCP complications ¹⁴

	Mild	Moderate	Severe
Bleeding	Clinical evidence of bleeding (ie not just endoscopic) Hemoglobin drop <3g No need for transfusion	Transfusion: 4 units or less No angiographic intervention or surgery	Transfusion: 5 units or more or intervention (angiographic or surgical)
Perforation	Possible, or only very slight leak of fluid or contrast dye Treatable by fluids and suction for 3 days or less	Any definite perforation treated medically for 4-10 days	Medical treatment for more than 10 days or intervention (percutaneous or surgical)
Pancreatitis	Clinical pancreatitis: amylase at least thrice the upper limit of normal at more than 24 hours after the procedure requiring admission or prolongation of planned admission to 2-3 days	Pancreatitis requiring hospitalization for 4-10 days	Pancreatitis requiring hospitalization for more than 10 days, or hemorrhagic pancreatitis, phlegmon, or intervention (percutaneous drainage or surgery)
Infection (cholangitis)	>38 degrees Celsius at 24-48 hours	Febrile or septic illness requiring >3 days of hospital treatment or endoscopic or percutaneous intervention	Septic shock or surgery

Table II: Patient Characteristics

Age at time of ERCP (years)	
mean (sd)	57.6 (19.8)
18-44 years	283 (26.4%)
45-64 years	357 (33.3%)
> 65+ years	432 (40.3%)
Gender	
Female, n (%)	522 (63.1)
Race	
Caucasian	688 (83.2%)
African American	15 (1.8%)
Other/unknown	124 (15.0%)
Charlson index at time of ERCP¹²	
mean (sd)	3.2 (3.2)
BMI at time of ERCP	
mean (sd)	28.5 (7.2)
< 25	341 (32.4%)
25-34	517 (49.1%)
35+	194 (18.4%)

ERCP – endoscopic retrograde cholangiopancreatography

BMI – body mass index

Table III: Procedural Characteristics

	(%)
Cholecystectomy within 30 days prior to ERCP	113 (10.5)
Altered anatomy	21 (2.0)
Anticoagulation	20 (1.9)
Prior ERCP	277 (25.8)
Biliary indications	975 (91.0)
Cholangitis	56 (5.2)
Cholecystitis	41 (3.8)
Bleeding	4 (0.4)
Choledocholithiasis	500 (46.6)
Malignant stricture	116 (10.8)
Hilar stricture	5 (0.5)
Benign stricture	46 (4.3)
Ca pancreas	21 (2)
Papillary stenosis	8 (0.7)
Ca ampulla	14 (1.3)
Anastomotic stricture	29 (2.7)
Post cholecystectomy	69 (6.4)
Suspected SOD	19 (1.8)
PSC	21 (2)
Bile leaks	23 (2.1)
Biliary colic	307 (28.6)
Biliary dilation	27 (2.5)
Stent removal	52 (4.9)
Elevated AST and ALT	76 (7.1)
Pancreatic indications	217 (20.2)
Acute pancreatitis	135 (12.6)
Recurrent acute pancreatitis	34 (3.2)
Chronic pancreatitis	17 (1.6)
Cyst	8 (0.7)
Duct leak	9 (0.8)
Duct stricture	7 (0.7)
Acute fluid collection	7 (0.7)
Chronic fluid collection	18 (1.7)
Necrosectomy	14 (1.3)
Inpatient	606 (56.5)

Therapeutic	889 (82.9)
Difficulty grade	
I	152 (14.2)
II	494 (46.1)
III	297 (27.7)
IV	129 (12.0)
Trainee present	667 (62.2)
Anesthesia	
Conscious sedation	1030 (96.1)
Fentanyl	51 (4.8)
Versed	1028 (95.8)
Benadryl	6 (0.6)
Demerol	979 (91.2)
Phenergan	90 (8.4)
Droperidol	25 (2.3)
General (or propofol)	42 (3.9)
Peri-ampullary diverticulum	117 (10.9)
Biliary sphincterotomy	620 (57.8)
Precut biliary sphincterotomy	125 (11.7)
Biliary stent placed	185 (17.3)
Pancreatic sphincterotomy	13 (1.2)
Pancreatic duct stent placed	59 (5.5)
Ampullectomy	7 (0.7)
Transgastric/transduodenal drainage	16 (1.5)
Sphincterotomy bleeding noted during procedure	45 (4.2)

ERCP – endoscopic retrograde cholangiopancreatography

AST – aspartate aminotransferase

ALT – alanine aminotransferase

Table IV: Procedure Outcomes

	(%)
Success	041 (97.1)
Death	
During procedure	0 (0.0)
Within 30 days	26 (2.4)
Need for repeat procedure within 30 days	
ERCP	93 (8.7)
EGD	45 1 (4.2)
Number of readmissions within 30 days	273
Definitely related to procedure	62 (22.7)
Possibly related to procedure	6 (2.2)
Definitely not related to procedure	205 (75.1)
Surgery within 30 days	
Elective cholecystectomy	52 (4.9)
Elective Whipple	16 (5.9)
Other elective	11 (4.0)
Emergent cholecystectomy	6 (2.2)
ERCP complications requiring readmit	53 (4.9)
Pancreatitis	26 (2.4)
Mild	18
Moderate	8
Severe	0
Infection/cholangitis	16 (1.5)
Mild	6
Moderate	7
Severe	3
Bleeding	15 (1.4)
Mild	6
Moderate	8
Severe	1
Perforation	4 (0.37)
Mild	0
Moderate	0

Severe	4
--------	---

Table V. Multivariate analysis of risk factors for post-ERCP complications

Risk factor	Odds ratio (95% CI)	P-value
Age <45 vs ≥65	2.23 (1.03 – 4.84)	0.0498 *
Age 45-64 vs ≥65	1.3 (0.62 – 2.72)	0.6697
Female gender	1.2 (0.61 – 2.21)	0.6412
BMI <25 vs ≥35	0.84 (0.40 – 1.74)	0.1972
BMI 25-34 vs ≥35	0.31 (0.14 – 0.72)	0.0024 *
No previous ERCP	2.22 (1.04 – 4.75)	0.0394 *
Outpatient ERCP	5.4 (2.6 – 11.4)	<0.0001 *
Pancreatic duct cannulation	2.7 (1.4 – 5.1)	0.0026 *
Absence of trainee	1.36 (0.72 – 2.59)	0.3487
Intraprocedure sphincterotomy bleeding	10.0 (3.8 – 26.1)	<0.0001 *
Difficulty grade 1 vs 4	0.11 (0.02 – 0.54)	0.0204 *
Difficulty grade 2 vs 4	0.45 (0.18 – 1.14)	0.9199
Difficulty grade 3 vs 4	0.94 (0.42 – 2.13)	0.0129 *